Protective Efficacy of a Borrelia burghdorferi BB0172 Derived-Peptide Based Vaccine Formulation in the Murine Model Against Lyme Disease by Hassan, Wisam Salim
PROTECTIVE EFFICACY OF A Borrelia burgdorferi BB0172 DERIVED-PEPTIDE 





WISAM SALIM HASSAN  
 
Submitted to the Office of Graduate and Professional Studies of 
Texas A&M University 
in partial fulfillment of the requirements for the degree of 
 
DOCTOR OF PHILOSOPHY 
 
Chair of Committee,  Maria D. Esteve-Gasent 
Committee Members, Thomas Ficht 
 Linda L. Logan 
 Luc R. Berghman 




Major Subject: Biomedical Sciences 
 





Lyme disease (LD) is the most prevalent tick-borne disease in the US. The 
disease in humans is characterized by the development of a characteristic skin rash 
(erythema migrans), arthritis, cardiac and neurological signs. Vaccination is the most 
efficient preventive measure that could be taken to reduce the incidence of the LD 
around the globe; however at present no vaccine is available for human use. To date, 
extensive research has been devoted to develop a protective vaccine for use in humans. 
Nonetheless, it is challenging to find a conserved antigen to combat the heterogeneity 
within the Lyme spirochetes. Also, the complex biology of Borrelia species and 
alterations in the expression of outer surface membranes, put another burden to generate 
effective LD vaccines. In this work, PepB, a BB0172-derived peptide was evaluated in 
scaffolded and conjugated formulations as a vaccine candidate in murine model of LD.  
Overall, we observed that, when animals are immunized with pepB conjugated to 
the tetanus toxoid, they develop high antibody titers that induce protection when animals 
are infected by needle inoculation. Furthermore, sera from immunized individuals 
showed bactericidal properties. Finally, the peptide conjugations tested did not protect 
against the tick infection by clearing infection, but a significant reduction in bacterial 
burden was observed in immunized groups compared to control groups. Therefore, we 
conclude that PepB conjugated antigens can serve as an alternative to prevent Lyme 
disease; nevertheless further studies will be needed to evaluate further delivery methods 
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INTRODUCTION AND LITERATURE REVIEW  
 
Lyme disease (LD) is a zoonotic tick-borne disease caused by bacterial 
spirochetes within the Borrelia burgdorferi sensu lato complex. LD was originally 
recognized in 1976 in Lyme, Connecticut in the United States based upon prevalence of 
rheumatoid arthritis among children [1]. LD is the most prevalent vector-borne disease 
in both Europe and North America. In the US, more than 30,000 cases of LD are 
reported annually to the Centers for Disease Control and Prevention (CDC). On the other 
hand, according to the European Centre for Disease Prevention and Control (eCDC), 
around 85,000 cases are reported annually in Europe. LD in humans is characterized by 
diverse dermatologic, neurologic, rheumatologic, or cardiac abnormalities. The disease 
is prevalent in temperate regions of the world (North America, Europe, and parts of 
Asia), where associated competent Ixodes spp. tick vectors are present.  
The causative agent of LD, B. burgdorferi sensu lato complex, is classified 
within the Phylum Spirochaetes, Order Spirochaetales, Family Spirochaetaceae, and 
includes over 20 different genospecies, of which some have not been reported to cause 
disease [2]. Nevertheless, Lyme disease in humans is primarily caused by three 
genospecies of B. burgdorferi sensu lato complex, which include Borrelia burgdorferi, 
B. afzelii and B. garinii [3]. These spirochetes are found geographically throughout the 
temperate regions of the world. In Europe and Asia, B. afzelii, B. burgdorferi sensu 




borreliosis, whereas B. burgdorferi s.s. is the main etiologic agent of LD in North 
America [4]. However, a novel genospecies B. mayonii has been recently described to 
cause LD infection, and was isolated from patients in the upper midwestern US. B. 
mayonii causes different clinical outcomes as compared to infection with B. burgdorferi 
sensu stricto, such as nausea, vomiting, diffuse macular rash, and high number of 
circulating spirochetes in the blood, similar to what is observed in relapsing fever 
Borrelial infection[5]. It has been shown that LD spirochetes have different tissue 
tropism as B. burgdorferi s.s. is mainly arthritogenic, B. afzelii causes skin infections, 
and B. garinii is mainly neurotropic [6]. 
Etiologic organisms, vectors and pathogenesis 
Ixodes ticks are responsible for transmitting Lyme Borrelia infection. The main 
tick vectors in Europe is Ixodes ricinus [7], whereas in Asia the vector is Ixodes 
persulcatus [8]. In the United States, LD is commonly present in the northeastern and 
upper midwestern states. In these regions of the country, the disease is transmitted by 
Ixodes scapularis ticks, while Ixodes pacificus is responsible for the transmission of B. 
burgdorferi in the Pacific coast states [9]. In addition, the blacklegged tick (I. 
scapularis) is also responsible for transmission of other human pathogens including 
those causing anaplasmosis, babesiosis, Relapsing fever Borrelia miyamotoi, 
ehrlichiosis, and Powassan virus disease [10]. Ixodes ticks are distributed throughout the 
northern hemisphere [11]. Their life cycle comprised three blood-feeding life stages 
including larva, nymph, and adult, and it is completed in an average 2-year period. 




they feed on an infected reservoir host; furthermore, this bacterium is maintained to the 
subsequent stages, this is also known as trans-stadial transmission [12, 13]. Thus, after 
molting, infected nymphs are able to infect naïve or infected competent hosts during the 
next blood meal, spreading the LD causative agent. In fact, ticks in different 
developmental stages are able to acquire Borrelia and transmit Borrelial cells to other 
susceptible hosts. However, in northeastern US, adult ticks are not significant in disease 
transmission and maintaining Borrelia burgdorferi in its enzootic cycle, since adult 
females feed primarily on large mammals such as deer, which is important for tick 
mating [14], but are not competent hosts for the pathogen. 
Most ecological studies have been done in northeastern US. Under these 
environmental conditions, nymphs are generally responsible for the transmission of 
Borrelial pathogens to humans and companion animals, especially in late spring and 
summer seasons. I. scapularis ticks feed on a wide range of hosts, ranging from small 
mammals such as mice and rabbits, to larger mammals such as foxes, skunks and white-
tailed deer. Humans, dogs and horses are considered incidental hosts, and may develop 
signs of B. burgdorferi infection and disease [15, 16]. Similar to what is observed in 
other Ixodid ticks [17], the feeding process of the adult female Ixodes scapularis tick can 
last up to 12 days, while nymphal stages can be feeding for up to 8 days. Therefore, in 
humans, the risk of LD increases after 36 to 48 hours from tick attachment. Conversely, 
studies have found that in animal models, spirochetal transmission can happen in less 




In the tick vector, spirochetes are acquired while feeding from an infected host. 
Spirochetes will colonize, and subsequently retained in the tick midgut through the 
different developmental stages (trans-stadial transmission). When infected ticks attach to 
a naïve host, B. burgdorferi will migrate from the midgut to the salivary glands of ticks 
upon feeding, and from there, to the mammalian host skin. That migration is facilitated 
by the differentially regulated borrelial outer surface proteins A and C (OspA and OspC) 
[19-21]. Borrelia burgdorferi cells in the tick midgut express high amount of OspA 
which acts as a docking protein that will interact with the Tick Receptor for OspA 
(TROSPA) anchoring B. burgdorferi to the tick [19]. Upon feeding, OspA expression is 
downregulated [19, 22] allowing Borrelial cells to be released from the midgut, migrate 
to the hemolymph and from there to the salivary glands where they can get injected in 
the host. At that stage, OspC expression is upregulated, allowing the binding of tick 
saliva proteins to the surface of borrelial cells, protecting B. burgdorferi from the host 
immune system, aiding in dissemination once in the host [23, 24]. Homologs genes of 
TROSPA have been identified not only in Ixodes scapularis (vector of B. burgdorferi in 
the USA), but also in I. ricinus, the tick species transmitting the infection in Europe [25], 
and I. persulcatus, the species transmitting Borrelia in Asia [26].  
As mentioned above, B. burgdorferi has the ability to alter its gene expression as 
it migrates from the tick vector to the vertebrate host. This differential gene expression is 
key to ensure their survival in disparate environments found along its life cycle [21, 27]. 
Once the infected tick starts its blood meal and blood flows inside the midgut, B. 




TROSPA. At the same time, there is upregulation of the borrelial OspC, and the bacteria 
signal cellular division while they migrate to the salivary glands. Overall, a number of 
genes will be differentially expressed in B. burgdorferi as it migrates from the tick to the 
host in order to adapt to a changing environment. This cascade of events enhances 
bacterial migration to the tick salivary glands, and then transmission to the mammalian 
host. After localizing to the salivary glands, B. burgdorferi is inoculated with the tick 
saliva into the host. During feeding, ticks are able to suck up blood to meet their 
nutritional need, and saliva with excess water and ions that are not essential for the tick 
are streamed back to the host, generating cycles of sucking and spitting that allow the 
transmission of pathogens [16, 28]. Examples of differentially expressed genes in B. 
burgdorferi are summarized in Table 1-1. 
Tick feeding is facilitated by tick saliva, which contains many components that 
allow ticks to cement to the host and acquire its blood meal. In addition, tick saliva has a 
significant role in transmission of spirochetes. Saliva secretions have several compounds 
that have different functions including reduce pain sensation, reduce inflammation at the 
bite site, increase blood flow, and anticoagulants that will facilitate pool feeding. In the 
presence of saliva proteins, ticks feed by damaging host’s skin and taking up blood that 
pools under the host tissues [29-32]. It has been found that tick saliva is able to enhance 
transmission and infection of B. burgdorferi versus studies where the inoculated 
spirochetes are not associated with saliva proteins [33-35]. For example, the salivary 
protein Salp15 binds to spirochete via interaction with its outer surface protein C 




activation of CD4 (+) T cells [35-37]. Therefore, OspC has been shown to facilitate 
transmission and infection of B. burgdorferi into host organisms [35, 38]. Another 
example of saliva protein is the tick salivary lectin pathway inhibitor (TSLPI). This 
protein enhances transmission and acquisition of B. burgdorferi by inhibiting the host 
lectin complement pathway, resulting in reduced chemotactic and phagocytic activity of 
neutrophils, and diminished spirochete lysis [33]. 
 
Table 1-1: Major differentially regulated genes in Borrelia burgdorferi  
Gene Location Host  Function References 
ospA (outer surface protein 
A) 
lp54 Tick Lipoprotein; binds Tick Receptor for 
OspA (TROSPA) 
[27, 39, 40] 
bptA (Borrelia persistence in 
ticks A)  
lp25 Tick/ 
Mammals 
Lipoprotein; necessary for tick 
persistence 
[41, 42] 
bicA ( Borrelia iron- and 
copper- binding protein A) 
formerly napA 
Chrom Tick Necessary for persistence in ticks  [43, 44] 
bba52 lp54 Tick Outer membrane protein; functions in 
transmission 
[45] 
bb0365 Chrom Tick Lipoprotein; necessary for persistence in 
tick 
[46] 
ospC (outer surface protein 
C) 
cp26 Tick Immune evasion; required for infectivity [27, 39, 40] 
vlsE (variable major protein-
like sequence, expressed) 
lp28-1 Mammals Immune evasion; required for infectivity, 
expressed after OspC 
[39, 47] 
dpbA/B (decorin binding 
protein A/B) 
lp54 Mammals Adhesin; binds 
decorin/glycosaminoglycans 
[48] 




Adhesin/Immune evasion; Binds Factor H [49] 




Adhesin; binds heparan 
sulfate/glycosaminoglycans 
[50] 
bb0172 Chrom Tick/ 
Mammals 
Adhesin; binds integrin α3β1 [51] 
bbk32  lp56 Tick/ 
Mammals 




acquiring surface protein A) 
lp54 Tick Immune evasion; Binds Factor H [54, 55] 
p66 Chrom Tick/ 
Mammals 










Transporter; Putatively binds Sodium 
Acetate or Sodium Bicarbonate 
[60] 




Tick histamine release factor (tHRF) is another component of tick saliva that 
stimulates histamine release in the host, leading to increased blood flow and vascular 
permeability. The tHRF has been shown to have a role in tick feeding and borrelial 
transmission in mice [61]. Therefore, it is important to consider a method of borrelial 
infection in vaccine studies, as there is a significant difference when animals are 
challenged with needle protocol vs using tick model of infection [62].   
Differential gene expression of Lyme disease spirochetes 
The changes in gene expression of spirochetes is the key role for their survival in 
two disparate environments, the tick vector and vertebrate host. In unfed tick conditions, 
spirochetes reside in the tick midgut, and during feeding the flowing of blood in the 
midgut induces migration of spirochetes to the salivary glands, and then transmission to 
mammalian host. At the same time, through differential gene expression, spirochetes 
successfully adapt to the new mammalian host environment. In laboratory setting, to 
study differential gene expression of spirochetes requires conditions similar to those 
described above. To mimic flat tick conditions, spirochetes are grown in BSK-II media 
at 23°C and a pH of 7.6. On the other hand, to mimic tick feeding conditions, bacteria 
are incubated at 37°C and a pH of 6.8. To study the pattern of gene expression, 
spirochetes grown and adapted to flat-tick conditions are shifted to grow under feed tick 
conditions, and the spirochetes can be analyzed before adaptation [27, 39, 42, 44, 55, 63, 
64]. Therefore, this is an in vitro strategy that can help understanding differential gene 




The outer membrane of B. burgdorferi lacks the lipopolysaccharide found in 
gram negative organisms, instead B. burgdorferi has a high density of lipoproteins, some 
which have been shown to be differentially expressed [42, 65, 66]. These outer surface 
proteins are critical for bacterial survival, metabolism, and adhesion within the vector 
and/or host environment [67]. Also, surface exposed outer proteins are immunogenic and 
play a vital role in bacterial pathogenesis; therefore, they are effectively considered as 
targets for anti-Lyme vaccines [68].  
Historically, the development of LD vaccine has been based on modifications of 
either the outer surface protein A (OspA) or C (OspC). The first and only licensed 
human Lyme vaccine was an OspA based vaccine, LYMErix by SmithKline Beecham 
[69]. It was withdrawn from the market in 2002 due to lack of interest and potential side 
effects associated with its use. This vaccine formulation targeted the Borrelial OspA 
lipoprotein, which is expressed when the pathogen is in the arthropod tick vector. When 
expressed, OspA mediates the attachment of spirochetes to the tick mid-gut via its 
receptor (TROSPA) [19]. The other important differentially expressed protein is outer 
surface protein C (OspC). This lipoprotein is expressed during mammalian infection, and 
it facilitates transmission of Borrelia sp. from the tick vector to the mammalian hosts 
[70]. The OspC has been used in several anti-Lyme vaccine formulations in dogs [71-
76]. Other examples of products of differentially regulated genes of B. burgdorferi that 
have been proposed as vaccine candidates are decorin binding protein A (DbpA), 
BBK32, and BB0172 [77-79]. DbpA and BBK32 are upregulated proteins within the 




adhesive matrix molecules (MSCRAMM) protein family, and they mediate binding of B. 
burgdorferi to extracellular matrix proteins of the host. Therefore, they enhance bacterial 
virulence and pathogenesis through colonization and dissemination of spirochetes in the 
host [80, 81].  
B. burgdorferi has the variable major protein-like sequence, expressed (VlsE), 
which is a surface protein characterized by antigenic variation. This is an 
immunodominant antigen expressed by B. burgdorferi when growing in mammalian 
tissues. In brief, the vls (Vmp- like sequence) locus is located on a 28-kilobase linear 
plasmid (lp28-1) of B. burgdorferi B31, and comprises an expression site (VlsE) and 15 
non-coding vls cassettes. Different antigenic variants of VlsE are expressed by 
recombination between segments of the expression site and the silent cassettes [82, 83]. 
Therefore, VlsE play a role in evasion of the host immune system and persistence in the 
infected host. It has been predicted that over 120 distinct potential lipoproteins are 
encoded by about 8% of B. burgdorferi B31 genome [84]. 
Pathogenesis of Lyme disease 
Lyme disease (LD) is a multi-systemic disease caused by infection with the 
spirochetal bacteria Borrelia burgdorferi sensu lato (sl), and it is characterized by fever, 
arthralgias, myalgias, and erythema migrans [85]. In humans, the early infection with 
Borrelia burgdorferi sl, also known as localized infection, is characterized by 
appearance of an erythematous skin lesion known as Erythema Migrans (EM, the bulls-
eye rash) at the site of the tick bite [86]. The EM lesion appears within 1-30 days after 




second stage of the early LD, or disseminated infection. In this state, the disease is 
characterized by systemic symptoms of infection such as fever, malaise, headache, 
myalgias, arthralgias, and dizziness [87, 88], also known as flu-like symptoms. In this 
state, cardiac involvement may be present, and some infected individuals show 
neurological signs within weeks to months following infection. The clinical picture of 
the patients in the third stage of LD, or persistent infection, is mainly manifested by 
arthritis. This stage usually develops following several months to years after the initial 
infection with Lyme Borrelia species [11, 89]. In fact, Lyme arthritis in children was the 
cause for the recognition and identifying of LD by Dr. Alan Steere in Connecticut in 
1977 [1]. It is estimated that about 60% of untreated patients develop Lyme arthritis 
manifested clinically by joint pain and swelling, and it is especially affected large joints 
such as knee [90].  
Pathogenesis of Lyme arthritis is initiated when spirochetes are frequently 
localized in joints or periarticular tissues during the dissemination phase of infection 
[91]. In most cases, the early stages of Lyme arthritis are asymptomatic, but later due to 
stimulation of antibody production and inflammatory cells response, the signs of clinical 
arthritis become evident [92].  The infected individuals respond to antibiotic treatment 
especially during the early stages of infection; however, if the treatment of LD is 
neglected, it will lead to sever rheumatologic, cardiac, and neurologic complications. 
Recently, and after many years of controversy [93], Post-Treatment Lyme Disease 
Syndrome (PTLDS) has been characterized by researchers at John Hopkins [94]. In this 




abnormalities in PTLDS patients, standardized symptom questionnaires, showed 
significantly poor health related quality of life compared to control groups. In addition, 
PTLDS patients presented with musculoskeletal pain, sleep disorder, depression and 
fatigue that could be detected only when using the so mentioned standardized 
questionnaires. Thus, PTLDS is a chronic illness that occurs following standard 
antibiotic treatment for early or late LD, and it has been reported in about 10-20% of 
treated patients [95]. 
Diagnostic measures of Lyme disease 
In LD, the infection can be subclinical without any symptoms, but in clinical 
disease cases, signs such as EM, arthritis, neurological signs are apparent for clinical 
diagnosis. Microbiological isolation is still the ‘gold standard’ for diagnosis of bacterial 
infections. However, some infectious agents such as Borrelia burgdorferi cannot be 
isolated on selected media in a timely manner and compatible with diagnostic efforts. 
Therefore, alternative diagnostic methods can be used such as direct detection of 
pathogen, indirect serological tests, and other molecular techniques such as PCR [96, 
97]. Lyme borreliosis is a disease with diverse clinical manifestations, and it can be 
misdiagnosed especially if physicians are not aware of the full picture of the LD. The 
CDC recommends using a two-tiered serological protocol as the most reliable diagnostic 
approach to increase test specificity in the lab diagnosis of LD samples. In the two-tiered 
protocol, the serological Enzyme Immuno Assay (EIA) is used to screen sera from 
infected individuals. EIA such as ELISA, chemiluminescence immunoassays (CLIA), 




ability to detect specific IgG and IgM antibodies [98].  Initially, the first step of the 
protocol includes utilizing an enzyme immunoassay (EIA) to detect antibody response 
against either the VlsE C6 antigen or whole-cell Borrelia lysate. Then, confirmation of 
the positive or borderline results with the second tier, consisting in immunoblotting 
against whole-cell Borrelia lysate or other significant antigens [99-101]. In Europe, the 
validity of using a single serological test in diagnosis of Lyme borreliosis is questionable 
regarding its adequate sensitivity and specificity to use it alone [102-105]. The design of 
a single immunoassay to detect Lyme borreliosis is challenging due to presence of high 
biodiversity of Borrelia genospecies in Europe [103, 105]. Therefore, other serological 
tests such as indirect immunofluorescence, complement fixation and indirect 
hemagglutination assays are currently deemed inappropriate to use for diagnosis of LD 
[100, 106].  
In general, duration of the disease will determine the dominant immunoglobulin 
isotype at the time of testing; therefore, serum will be evaluated for either IgM or IgG 
antibodies based on whether the individual is early or latter in the infectious process. 
Basically, immunoblotting is used to test samples for IgM in the early stage of disease, 
less than or equal to 30 days. Whereas, IgG antibody can be detected later in serum 
samples [107]. Immunoblot results for IgM are considered positive if a sample shows at 
least 2 of 3 signature bands (OspC, BmpA, Fla), and 5 of 10 signature bands for positive 
IgG results (OspC, BmpA, Fla, and antigens designated by their molecular weights: 18, 




Current methods for the serological diagnosis of LD have few limitations such as 
lag of seroconversion by weeks following infection, inability to recognize active 
infection, past infection or reinfection, and no predictive value to track progression of 
acute LD to a chronic state [111]. Therefore, researchers try to develop new diagnostic 
methods that can overcome these restrictions. Among these tools, detection of DNA by 
molecular approach can be used for diagnosis of LD such as multiplex real-time PCR 
[112], and next generation sequencing (NGS). The multiplex assays allow for detection 
of multiple pathogens simultaneously by using a variety of probe fluorophores that can 
be detected at different wavelengths. Multiplex real-time PCR assay is useful to screen 
samples for more than one tick-borne disease pathogen at a time [113]. In a study 
involved human blood samples, multiplex qPCR was used to detect Babesia microti and 
B. burgdorferi. The results of that study showed 80% sensitivity for detection of LD and 
B. microti co-infection [114]. In regard to NGS, the various NGS platforms were 
developed for analyzing full genome sequencing, and identification of potential genetic 
diseases [115]. Moreover, NGS has been further expanded to include diagnostic 
applications that can be used to identify various infectious agents[116]. It has been 
studied that deep sequencing of the hypervariable outer surface protein C locus (ospC) 
was used to detect B. burgdorferi in Ixodes scapularis ticks collected from New York 
State, USA. It has been shown from that study that targeting the conserved region of 
intergenic sequences has significant implications in diagnosis and quantification of LD 
spirochetes in clinical and wildlife specimens [117]. Furthermore, other indirect methods 




biomarkers that support early LD diagnosis. For example, a European study showed that 
analysis of cytokine CXCL13 in cerebrospinal fluid (CSF) from suspected cases with 
Lyme neuroborreliosis (LNB) was a useful diagnostic tool. In fact, it supported the LNB 
diagnosis in children with short symptom duration [118]. Also, ELISpot assay was used 
for diagnosis of Lyme borreliosis in a clinical study included Borrelia positive patients. 
It showed promising results as a new diagnostic tool with higher specificity and 
sensitivity compared to the western blot assay [119]. 
Treatment of Lyme disease 
The early manifestations of LD, both localized and disseminated forms, are 
characterized by spontaneous healing without medical intervention. Treatment in such 
cases is recommended to avoid the sequelae of the disease, especially neuroborreliosis 
and Lyme arthritis. In the US, more than 80% of untreated patients developed Lyme 
arthritis [120]. Whereas in Europe, patients may develop Acrodermatitis Chronica 
Atrophicans (ACA) [121, 122]. In vitro studies have shown that Borrelia burgdorferi s.l. 
strains are susceptible to most penicillin, tetracyclines, many second and third generation 
cephalosporins and macrolides [99, 123, 124]. Early localized LD can be effectively 
treated with doxycycline, phenoxymethylpenicillin and amoxicillin, whereas the early 
disseminated form is treated with intravenous injection of ceftriaxone or penicillin. 
However, researchers have found that an oral administration of doxycycline is effective 
for treatment of Lyme neuroborreliosis in Europe [125, 126]. However, applying 




tick-populated areas, wearing long sleeved and long pants clothing, tick observation, and 
use of repellents [127, 128].  
Prevention of Lyme disease  
Ticks are ranked second to mosquitoes worldwide for transmitting infectious 
disease agents to humans [129]. They are transmitting a wide diversity of viral, bacterial, 
and protozoal infections among animals and humans. In many temperate regions around 
the world, tick-borne diseases are prevalent and considered the most important vector-
borne infections. Among these, Lyme borreliosis caused by Borrelia burgdorferi and 
transmitted by Ixodes spp ticks. In endemic areas, exposure of susceptible hosts to 
infected ticks is associated with increased risk of LD infection. Therefore, minimizing 
the risk of tick bites can significantly reduce the risk of tick-borne diseases. This can be 
accomplished by applying prophylactic measures such as avoiding tick-infested areas, 
wearing protective, covered clothing, and applying tick repellents and acaricides. In 
addition, permethrin treated clothes can be used especially for individuals who stay long 
period of times in tick infested areas. These clothes showed reduction in tick bites of 
93% in people wearing permethrin treated clothes compared with controls [130]. Also, 
removal of the attached ticks with forceps, especially following hiking, camping, and 
other outdoor activities [131]. Moreover, school campuses, neighborhood backyards, 
parks, and other places are considered also important avenues for transmission of tick-
borne diseases [132]. The important considerations to prevent tick bites should be 




that Borrelia infections were reduced in people who were exposed to prior educational 
opportunities regarding ticks and how to prevent tick bites [133].  
Companion animals especially dogs can carry ticks to humans, particularly in 
endemic areas, as they are considered significant risk factors for disease acquisition 
because they are more frequently exposed to infected ticks [134, 135]. Therefore, 
treatment of these animals with anti-tick preparations and or available canine Lyme 
disease vaccines are recommended [128]. 
Lyme disease Vaccine Development 
Immunization studies started shortly after discovery of B. burgdorferi in 1977. 
Johnson and collaborators showed that passive transfer of immune rabbit serum to 
hamsters protected against B. burgdorferi infection [136]. Later, the same team 
evaluated immunization of hamsters with whole, inactivated B. burgdorferi. In brief, 
naïve hamsters were immunized with a single dose of inactivated B. burgdorferi and 
challenged with a dose of 1,000 × ID50 B. burgdorferi cells. The group of animals which 
immunized with 50 µg of B. burgdorferi cells (dry weight) showed 86-100% protection 
[137]. Therefore, these studies have shown that humoral immune response is responsible 
for protection against LD. In addition, the study of Schmitz and collaborators [138] 
showed that passively immunized hamsters with serum from infected animals were 
protected from development of arthritis. Moreover, serum ability to confer protection 
was associated with the development of borreliacidal antibodies [138, 139]. Collectively, 
those studies showed that humoral immune response induced by vaccination is able to 




Since then, researchers started focusing their efforts on identifying major 
epitopes of B. burgdorferi that are able to induce a protective immune response. Of 
these, outer surface proteins gained significant interest. Previous studies revealed that 
immunized mice with OspA, either by active or passive routes, were protected from 
infection with B. burgdorferi [140, 141]. In addition, it has been shown that removal of 
OspA antibodies from Lyme arthritis patient’s serum, was unable to confer protection in 
passively immunized hamsters [142]. Likewise, it has been shown that severe combined 
immunodeficiency mice (scid) receiving OspA-specific monoclonal antibody were 
protected against B. burgdorferi infection [143]. Therefore, the above studies provided 
support to use OspA-based vaccines in human and companion animals. Historically, the 
development of LD vaccine has been based on modifications of either the outer surface 
protein A (OspA) or C (OspC). The first and only licensed human Lyme vaccine was an 
OspA based vaccine, LYMErix by SmithKline Beecham [69]. It was withdrawn from 
the market in 2002 due to lack of interest and potential side effects associated with its 
use. This vaccine formulation targets the Borrelial OspA lipoprotein, which is expressed 
when the pathogen is in the arthropod tick vector.  
During tick feeding B. burgdorferi migrated to the salivary glands of ticks, and 
then to the mammalian host. That migration is facilitated by the downregulation of OspA 
expression upon blood intake [22, 144]. Thus, OspA based vaccines are effective in 
conferring protective immunity by blocking the transmission of B. burgdorferi from the 
tick to the mammalian host [145]. In fact, the antibodies induced by the OspA vaccine 




administration of OspA formulated vaccine to small rodents (reservoir hosts) has been 
used to reduce the prevalence of B. burgdorferi in the mammalian reservoirs and the tick 
vectors, and break the enzootic cycle of the disease in nature, which might reduce the 
incidence of B. burgdorferi infection in human [146, 147]. In addition, in veterinary 
medicine, multiple OspA based vaccines have been used to immunize dogs against LD, 
such as Nobivac® Lyme from Merk Animal Health; LymeVax® from Fort Dodge and 
Recombitek® Lyme from Merial [75, 148]. Nevertheless, since specific antibodies have 
to neutralize B. burgdorferi while in the tick vector, individuals immunized with OspA 
vaccines need to maintain high antibody titers in order to have an effective vaccine. 
Researches from Valneva, Austria GmbH designed multivalent OspA-based vaccine 
derived from multiple OspA serotypes, which include B. burgdorferi (serotype 1), B. 
afzelii (serotype 2), B. garinii (serotypes, 3, 5 and 6) and B. bavariensis (serotype 4). 
Scientists incorporated C-terminal halves from 6 of the most clinically relevant OspA 
proteins in their vaccine candidate, but without including the hLFA-1 epitope [149]. This 
vaccine formulation, referred to as VLA15, has been tested in Europe through Phase I/II 
clinical trials, and it was showed to be safe and immunogenic [150, 151]. In addition, 
VLA15 conferred protection to immunized mice against challenge with four different 
Borrelia species [152]. Therefore, Phase III clinical trials will be pursued with the 
intention of evaluating efficacy [150].  
The other important differentially expressed protein during the transmission of B. 
burgdorferi from the tick vector to the mammalian host is outer surface protein C 




meal in the tick midgut until approximately 10 days post-transmission), and it facilitates 
transmission of Borrelia sp. from the tick vector to the mammalian hosts [70]. The OspC 
shows significant heterogeneity within Borrelia sp. isolates [153]. Therefore, in order to 
use a protective vaccine, any construct of OspC based vaccine is required to incorporate 
the heterologous potentially protective epitopes from different Borrelia sp. isolates. In 
fact, to generate a complete, broadly protective vaccine against LD using the OspC 
antigen, 34 distinct epitopes would be required [154]. Based on such observations, an 
octavalent, and chimeric OspC vaccine candidate has been evaluated [155], and a 
recombinant, heptavalent LD vaccine has been developed by Zoetis, VANGUARD ® 
crLyme, formulated to prevent LD in dogs [156]. It has been shown that OspC is an 
essential factor for establishing mammalian infection [157]. Hence, it induces immune 
response upon infection. Several studies showed that sera from patients with early LD 
have significant extensive reaction to OspC compared to OspA [110, 158, 159]. 
Moreover, it has been shown that patients with erythema migrans have prominent IgM 
response to OspC [110]. In addition, patients with various early LD manifestations 
showed moderate IgG response to OspC [160]. These findings reinforce the continued 
use of OspC as a vaccine candidate.  
LYMErix by SmithKline Beecham 
The U.S. Food and Drug Administration (FDA) approved the first recombinant 
OspA vaccine against LD, LYMErix by SmithKline Beecham (now GlaxoSmithKline) 
in December 1998. The vaccine was derived from the lipoprotein outer surface protein A 




interest and reported side effects [161]. Another recombinant OspA vaccine, ImmuLyme 
was generated by Pasteur Mérieux-Connaught (Swiftwater, Pennsylvania), and it was 
proved to be safe during phase I and phase II studies. However, ImmuLyme was not 
introduced to the public due to the company not proceeding to apply for licensure [162, 
163]. The LYMErix vaccine was designed for individuals aged 15-70, while ImmuLyme 
for individuals aged 18-92 [164]. Characteristics of human LD vaccines (LYMErix™ 
and ImuLyme™) are listed in Table 1-2. 
The LYMErix vaccine was instructed to use with aluminum hydroxide as an 
adjuvant, in 3 doses, and showed protection in about 80% of vaccinated individual 
against infection with B. burgdorferi [165]. The main drawback of this vaccine was to 
maintain high titer of OspA antibodies in the host, required to confer protection against 
borrelial infection [145, 166-168], since the antibodies will block the transmission of B. 






It has been suggested that structural similarity between some host proteins and 
OspA can induce an autoimmune reaction, which resembles Lyme arthritis [172]. It has 
been revealed that part of OspA (amino acids: 165-173), the immunodominant T cell 
epitope, has similarity to the human leukocyte function associated antigen-1 (hLFA-1) 
(amino acids: 332-340) [173, 174]. The HLA-DRB1*0401 and HLA-DRB1*0404 are 
found to present the OspA165-173, and its hLFA-1 homolog to T-helper cells, and induce 
an autoimmune reaction characterized by antibiotic resistant Lyme arthritis [174-177]. 
Prior to approval of the OspA vaccine field trials by the FDA, it was known, that 
vaccination with B. burgdorferi or its components may induce potential side effects such 
as arthritis. For instance, previous studies showed that immunized hamsters with OspA 
based antigen, developed arthritis following infection with B. burgdorferi [178]. In 
addition, OspA vaccination was correlated with cases of arthritis and neurological signs 
in humans [179, 180]. Furthermore, several reports have shown that vaccination with 









































Both vaccines were administered intramuscularly at a dose of 30 µg and a frequency of 0, 1, and 12 




whole Borrelia organisms are associated with severe arthritis following challenge of 
immunized mice with B. burgdorferi [181-184].  
Lyme disease vaccines for domestic animals 
Lyme borreliosis can also infect dogs and horses beside human. Infected ticks are 
able to transmit the infection to dogs and other animals as well. Companion animals 
primarily dogs are under the risk for tick exposure due to their outdoor activities. In 
dogs, the clinical manifestations are characterized primarily by Lyme arthritis, lameness, 
and some may develop Lyme nephropathy, although the majority of seropositive cases 
of Lyme borreliosis are asymptomatic or subclincally infected [185]. However, most 
cases of equine infection are asymptomatic [186, 187]. Nevertheless, the clinical disease 
in horses is characterized by neuroborreliosis, uveitis, lethargy, lameness, hyperesthesia 
and cutaneous pseudolymphoma [186, 188, 189]. In the US, seroprevalence studies of B. 
burgdorferi antibodies circulating among adult horses in endemic areas showed 
relatively high rates of 33% or greater indicating previous exposure to Lyme spirochetes 
[187, 190]. Also, Lyme borreliosis in cats is usually characterized by inapparent 
infection; however, the clinical signs may include fever, lethargy, and lameness [191-
193]. Whereas in cattle, infections with Borrelia-like spirochetes are rare, and can cause 
laminitis, stiffness and swollen joints, reduced milk yield, weight loss, and abortion in 
pregnant animals [194, 195].  
Currently, vaccine against Lyme borreliosis is available only for dogs, and there 
are 5 commercial licensed vaccines to use in North America, produced by 4 different 




Table 1-3: Available commercial vaccines for dogs against Lyme disease [196]  
Name of vaccine Company Borrelia Antigen Adjuvant 
Recombitek® 
Lyme 
Merial Recombinant OspA(monovalent) OspA Lipidation 
LymeVax®  Zoetis 
Bivalent whole –cell inactivated  
 
Bacterin (OspA containing strain 
and OspC strain) 
Aluminum hydroxide 
Duramune® Lyme Elanco 
Bacterin (OspA containing strain 
and OspC strain) 
Proprietary 
Nobivac® Lyme Merck 
Bacterin (OspA containing strain 










Wildlife vaccination Trials   
Zoonotic pathogens such as Lyme disease circulate between human and animal 
hosts including wildlife reservoir hosts. Therefore, preventing the transmission of 
pathogens in the vertebrate reservoir and/or within the arthropod vector is one of the 
methods that can be used to reduce the prevalence of vector borne diseases in humans 
and companion animals. Vaccination of vertebrate reservoir hosts can disrupt the 
zoonotic transmission cycle of pathogens, and reduce the infection rate in the arthropod 
vector. In the wildlife habitat setting, oral vaccination is recommended because it is not 
invasive, and is practical and cost-effective [197]. A bait vaccination approach has been 
successfully used to control rabies and plague in wildlife animals [198-201]. B. 
burgdorferi circulates in nature between tick vectors of the genus Ixodes and vertebrate 




[202-207]. Fikrig and collaborators [208] showed that mice immunized with 
recombinant outer surface protein A (rOspA) administered orally were protected against 
B. burgdorferi challenge. Another study [197] concluded that oral administration of 
purified OspA provided protection against systemic infection with B. burgdorferi to 
immunized mice. From this view, immunization of wild white-footed mice Peromyscus 
leucopus with OspA via subcutaneous inoculation reduced in the test sites (Connecticut), 
both prevalence of B. burgdorferi in I. scapularis nymphs, as well as human risk of 
contracting Lyme disease [146]. Such studies provided the baseline to develop an oral 
bait system to immunize mice with OspA [209] , to reduce pathogen burden in the 
arthropod vector. In addition, a study by Voordouw et al. [210] showed that oral bait 
vaccine derived from OspA significantly reduced transmission of B. burgdorferi from 
previously infected white footed-mice to feeding ticks. In addition, in the same 
mentioned study, the oral bait vaccine conferred protection in naïve white footed-mice 
against B. burgdorferi challenge. 
In general, oral vaccination of wildlife is considered a promising tool to reduce 
prevalence of infectious diseases in both human and animal hosts. However, it requires 
logistic support on a large-scale basis, from providing large quantities of vaccine, 
information related to ecogeographic patterns of targeted regions, and vehicles for 
distribution of baits, personnel and strategic planning. In regard to LD spirochetes, there 
are several vertebrate reservoir hosts that may not be targeted by the vaccine bait, and 
even not all the targeted animals will take the bait. The implementation of bait-based 




animals. Therefore, there will be a potential decrease in the numbers of infected tick 
populations that would reduce the incidence of LD in human and other susceptible 
animals, however the risk for exposure to LD spirochetes is still high especially in 
endemic areas. Thus, human LD vaccine is still required to reduce disease prevalence in 
the endemic and hyper-endemic areas.  
Conjugated vaccine 
Vaccination is the most effective method used for control infectious diseases. In 
more recent years, conjugated vaccines have emerged to improve immunogenicity of 
vaccines to combat a variety of infectious agents. Therefore, a number of molecules have 
been developed and used as carrier molecules for the generation of protective vaccines 
against different infectious diseases in humans. Among those that have been evaluated in 
preclinical and clinical studies, five carrier molecules have been used successfully in 
licensed vaccines, which includes diphtheria and tetanus toxoids, the Cross Reacting 
Material (CRM197), the outer membrane complex of Neisseria meningitidis serogroup B 
(OMPC), and the protein D derived from Haemophilus influenzae (PD) [211]. CRM197 
was isolated from Corynebacterium diphtheria C7 (β197)tox−, and it can also be 
produced by recombinant DNA methods in heterologous organisms. We initially 
selected tetanus toxoid and CRM197 in our current study because they are commercially 
available and have been shown to be safe for use in humans [212]. The incorporation of 
carrier proteins to polysaccharide antigens induces T-cell dependent antibody responses, 




of antibody titers with further doses [213]. In addition, not only the strength but also the 
type of T-helper cell response affects the quality of the T-cell help [214].  
OMPC has been used in Haemophilus influenzae type b conjugate [215] and 
pneumococcal conjugate vaccines [216]. PD is a 40 KDa cell surface protein derived 
from non-typeable H. influenzae, and has been used in a multivalent pneumococcal 
conjugate vaccine [217, 218]. Tetanus toxoid is a detoxified product of tetanus toxin, 
which is produced by Clostridium tetani cultures. 
The Cross Reacting Material (CRM197), a non-toxic mutant of Diphtheria toxin 
with a single nucleotide substitution.  In particular, nucleotide 197 was modified from G 
→ A inducing a change from Glycine in amino acid 52 in the wildtype molecule to 
Glutamic acid in CRM197 [219, 220]. This substitution resulted in loss of function, and 
therefore makes this molecule safe to be used as an immune system stimulation, and an 
excellent carrier molecule. Consequently, CRM197 is widely used as a carrier molecule 
for licensed conjugate vaccines such as in Haemophilus influenzae type b (Hib) and 
Streptococcus pneumoniae FDA approved vaccine Prevnar®13 [221]. Conjugate 
polysaccharide vaccines containing CRM197 as a carrier molecule have been used 
successfully worldwide to immunize hundreds of millions of people. Also, CRM197 
based conjugate vaccines such as Menveo® Menjugate®, and Meningitec® have been 
approved to use against Neisseria meningitidis infection [222]. In addition, several 
CRM197-conjugate polysaccharide vaccines are under further clinical and preclinical 




paratyphi, Mycobacterium tuberculosis, Staphylococcus aureus, Streptococcus 
agalactiae, and several pneumococcal conjugate vaccines [223-228].  
Contrary to Diphtheria toxin, CRM197 is a 58 kDa protein that is genetically 
modified to be non-toxic, and therefore detoxification process prior to use is not 
required. Furthermore, Diphtheria toxoid is immunogenic, but studies have suggested 
that the inactivation process might affect some T-helper cell epitopes. Thus, since 
CRM197 does not need to be detoxified through chemical treatment, it has enhanced 
carrier effect due to its intact T and B cell epitopes [227, 229]. The isolation of different 
cross-reacting forms of diphtheria toxin (CRMs) began in 1971, and the mutant form 
CRM197 was isolated in 1973 [230, 231]. The final optimized product was 
commercially available in the mid-1980s. Characteristics of CRM197 molecule is 











Table 1-4: Properties of CRM197 molecule 
Characteristics  Advantages References 
Widely used in commercially licensed 
vaccines  
Large-scale production and non-toxic 
mutant form of diphtheria toxin 
Indirect conjugation via a linker 
molecule 
Has conformational changes when 
reacting to monoclonal antibodies 
Binds to phospholipid bilayers  
Binds to different molecules and 
membranes independent of 
temperature and pH 
No need for chemical detoxification 
Maintain its three-dimensional 





Ticks and tick-borne diseases (TBDs) are distributed worldwide and considered 
major threats to human and animal health. Ticks can carry wide array of etiological 
agents including protozoal, bacterial, and viral pathogens. Currently, the CDC has listed 
16 tick borne diseases that can infect humans in the US. The most common TBDs in 
humans include Lyme disease, babesiosis, ehrlichiosis, Rocky Mountain spotted fever, 
anaplasmosis, tick-borne relapsing fever, and tularemia [239, 240]. In general, zoonotic 
diseases are of significant importance as they consider a major threat to public health. 
Specifically, LD is the most prevalent zoonotic tick-borne infection reported in the US. 
In fact, ticks are considered the exclusive, vital vehicle for transmission of LD to 
mammalian hosts [241]. Hence, control the expansion of ticks can significantly reduce 




acaricides to control ticks and the pathogens they transmit has been extensively used, 
and has shown some limiting factors such as development of tick resistance to these 
chemicals, and release of environmental contaminants [242-244]. Moreover, there are 
currently no available effective vaccines against most TBD agents, therefore there is a 
need to develop new strategies to control ticks and their associated agents [245]. One of 
these strategies is to interfere with the ticks feeding on mammalian hosts by using 
putative anti-tick vaccines [246]. In the absence of effective anti-tick vaccines, 
controlling ticks by chemical acaricides is the only reliable method used to eliminate 
these ectoparasites and protect animals, while humans are left with insect repellents, 
protective clothing and tick checks after outdoor activities as their only protection 
against TBDs [247, 248]. Several studies have evaluated the feasibility of immunizing 
animals with tick antigens, and study the effect of tick immunity on pathogen 
transmission and acquisition. Of special interest have been saliva proteins, due to their 
role in tick feeding and immune system evasion. Some researchers have evaluated the 
potential role of Salp15, a 15 kDa secreted salivary protein from Ixodes scapularis, as a 
potential tick vaccine. Salp15 protein has immunosuppressive traits, as it inhibits 
activation of CD4+ T cells, complement, and dendritic cells [249]. Thus, in previous 
studies, anti-Salp15 immunity induced 60% protection against Borrelia burgdorferi 
infection [250] in the mouse model.  
Another study showed that immunized mice with Salp25D, a 25 kDa secreted 
salivary protein from I. scapularis, had reduced spirochete acquisition by ticks. This 




the effects of reactive oxygen species produced by neutrophils [251]. Immunized mice 
with tick histamine release factor (tHRF), secreted salivary protein from I. scapularis, 
have markedly reduced bacterial burden in mice, and efficiency of tick feeding [61]. 
Moreover, implementing vaccine candidates derived from tick gut antigens had shown 
effectively reduction of tick engorgement on cattle [252]. On those lines, the study 
conducted by Kotsyfakis et al. [253] showed that immunized guinea pigs, with 
sialostatin L2, have reduced the feeding ability of I. scapularis nymphs. Moreover, it has 
been reported that immunized mice with the tick salivary lectin pathway inhibitor 
(TSLPI) from I. scapularis showed impaired bacterial acquisition and persistence in tick 
midguts, and 30% reduction of bacterial burden in the host [33].  
A novel approach: The VWFA domain containing proteins 
The Von Willebrand factor A (VWA) domain is well known for its presence in 
extracellular matrix proteins, integrin receptors, and cell adhesion proteins. Proteins 
containing these domains are found across Eukarya, Archaea, and Bacteria. Although it 
is primarily found within extracellular proteins, some proteins involved in essential cell 
functions, such as DNA repair or transcription, also contain VWA domains. Multiprotein 
complexes, in particular, commonly feature these domains, and VWA domain 
interactions may be essential to the assembly or functionality of these complexes. VWA 
domains exhibit classic Rossmann folds: β-sheets flanked by multiple α-helices in 
alternating sequence. Many have loops with a noncontiguous sequence motif called a 
metal ion-dependent adhesion site (MIDAS) where metal ions are bound. Protein-protein 




VWA domains take part in many important functions, including linkage of platelets to 
collagen during blood coagulation and interaction of integrins with collagen and other 
ligands. As such, mutations in these domains can lead to a variety of human diseases 
[254-256]. 
Subramanian et al. [257] identified new protein family VWFA domains in both 
spirochetes B. burgdorferi and Treponema pallidum. In fact, these novel proteins 
containing domains only previously recognized in eukaryotes. However, the comparative 
genome analysis revealed that the Borrelia VWFA domain containing proteins were not 
highly similar to the VWFA proteins in Treponema [257]. The membrane associated 
VWFA domains are similar to the extracellular adhesion molecule, thrombospondin-
related anonymous protein (TRAP), found in malarial protozoan Plasmodium [258]. 
TRAP has been shown to bind mammalian hepatocytes and heparin sulfate 
proteoglycans [259]. Therefore, as structurally similar to TRAP, it was expected that 
VWFA domain containing proteins in spirochetes are involved in bacterial adhesion to 
mammalian extracellular matrix [257]. In B. burgdorferi, four genes encoding for 
VWFA domain containing proteins were identified including bb0172, bb0173, bb0175, 
and bb0325 [255, 257, 260]. Among these genes, bb0172 was found to encode for an 
outer membrane protein of B. burgdorferi that binds to the human integrin α3β1, via its 
VWFA domain [51]. In regard to the other Borrelial VWFA domain containing proteins, 
BB0173 was shown to be an inner membrane protein with its VWFA domain exposed 
internally to the periplasmic space [261], with its expression was regulated by the 




To date, several attempts have been made to generate a protective vaccine to 
prevent LD in humans. Nonetheless, they have been considered ineffective to confer 
protection against LD caused by various genospecies of Borrelia, due to the fact that the 
antigens of these vaccines show high heterogeneity when compared among different 
serotypes of spirochetes. In our laboratory, vaccine studies showed promising results 
when using a short peptide (PepB), derived from the highly conserved VWFA-domain 
containing protein BB0172 [51]. Small and collaborators showed that the BB0172 
derived peptide confer protection in the murine model of LD when administered 
subcutaneously as a conjugate vaccine [79]. In addition, no histopathological signs were 
observed post-immunization in any of the examined tissues. Although the combined 
evidence supports the promise of PepB as an approach to Lyme vaccine development, 
there is a critical need to evaluate the therapeutic efficacy and safety of novel 
formulations that will improve protection in both humans and animals across different 









Central hypothesis and specific aims 
Based on the presented literature review, my central hypothesis is that 
implementing carrier and/or scaffolding molecules in conjugation with the vaccine 
candidate PepB, derived from BB0172, will increase the efficacy of the PepB vaccine 
formulation against Lyme disease in the murine model. The objective of this work is to 
evaluate a vaccine candidate derived from a highly-conserved B. burgdorferi von 
Willebrand factor A domain containing protein, using different antigenic platforms. 
Therefore, our study is significant because it exploits the conserved nature of BB0172 
protein allowing the generation of vaccine candidates that will diversify alternatives to 
control the spreading of Lyme disease in the US. 
The overall hypothesis was challenged through the completion of the following 
specific aims: 
Aim I: Evaluate the immunogenicity and efficacy of the PepB formulated in a 
protein scaffold derived from B. burgdorferi. 
Aim II: Evaluate protective efficacy of the CRM197 and Tetanus toxoid heavy 
chain conjugated PepB in the murine model for Lyme disease. 







EVALUATION OF IMMUNOGENICITY AND EFFICACY OF THE PEPB 




Protein scaffold is an alternative method used to generate immunogenicity of 
poorly or non-immunogenic antigens [262-264]. Naturally synthesized proteins with 
rigid, well-defined structure and intrinsic stability are considered effective scaffold that 
can be used for antigen presentation [265-267]. Some studies revealed that inserted 
epitopes into an unrelated scaffold protein structure was a feasible strategy to present the 
HIV-1 gp41 epitopes 2F5 and 4E10. In such experiments, author observed that after 
immunization, the scaffolded antigens produced significant high-binding affinity 
antibodies compared to the epitope peptide alone [264, 268].  Suitable scaffolds are 
molecules with sufficiently large regions at the molecular surface that are tolerant to 
substitutions or insertions without interrupting the integrity of the overall three-
dimensional structure [269]. Also, scaffolds are considered efficient immunogens in 
many respects to other antigen presentation platforms, including peptide conjugates 
[270]. 
Reverse vaccinology has enabled us to determine and define the antigenic map of 
various pathogens, and structural vaccinology, which tremendously assist in identifying 




pathogen-specific antigens as well [271]. Therefore, the epitope-based vaccination can 
be used to mainly target critical neutralizing epitopes, and avoid inducing non-protective 
antibodies in vaccinated individuals [272].   
There are a number of scaffolding alternatives such as Virus-Like Particles 
(VLPs) and backbone grafting. In the first case, virus-like particles (VLPs) have been 
used as vaccine development platforms for years. Furthermore, VLP scaffolds have been 
used to present immunogenic antigens from various viral, bacterial, or parasitic 
pathogens, known as chimeric VLPs [273]. Viral capsid proteins can be synthesized in 
vitro through exploiting the advancing biotechnology, and creating self-assembled, 
empty virus-like particles. In addition, these particles can be used as an adjuvant to boost 
the immune response [274-276]. Furthermore, VLPs can be presented by Antigen 
Presenting Cells (APC) and stimulate B and T- lymphocytes. Therefore, scientists have 
taken advantage of these immunogenic viral particles and used them as platforms to 
display different antigens with the objective of inducing a strong immune response 
[275].  
Backbone grafting is a strategy that implies using protein scaffolds as a 
presentation platform, in which a protein backbone can be engrafted with different 
epitopes [264, 277, 278]. Correia and collaborators [3] showed that a viral epitope, 
derived from respiratory syncytial virus and inserted in a protein scaffold based structure 
was able to elicit potent neutralizing antibodies [279].  
Borrelia burgdorferi has a single peptide transport system of the ABC 




permease (Dpp) transport systems that are found in other bacteria [280, 281]. BBA34 is 
a 61 kDa surface lipoprotein, and one of 5 oligopeptide permease A homologs in B. 
burgdorferi and is denoted as OppA5 [60]. Furthermore, BBA34 participates in the 
transport of solutes like acetate and bicarbonate. Moreover, BBA34 is a lipoprotein 
exposed to the periplasmic environment of the B. burgdorferi, and the bba34 gene is 
located on linear plasmid 54 (lp54). In addition, BBA34 is upregulated when the 
spirochetes are growing under tick feeding and mammalian host conditions [282]. In 
previous studies, Dr. Esteve-Gasent was able to demonstrate the immunogenicity of 
recombinant BBA34 lacking the lipidation target (personal communication, data not 
published). In addition to previous data from Dr. Esteve-Gasent, a former laboratory 
member, Dr. Christina Brock demonstrated the immunogenicity of BBA34:PepB in the 
murine model of Lyme diseases (Brock, C. PhD Thesis).  
Based on the evidences described above, the borrelial membrane protein BBA34 
was considered as a potential protein scaffolding molecule. Consequently, we 
hypothesized that by engrafting PepB into an exposed region of the borrelial protein 
BBA34, known as solute binding domain, we will be able to enhance the presentation of 
the PepB to the immune system, and therefore stimulate the generation of protective 






Materials and methods 
Cloning and expression of scaffolded antigen  
The scaffolded construct BBA34:PepB (BP) was synthesized in the expression 
vector pET23a by Genscript (Piscataway, NJ) with optimized codon usage for 
expression in Escherichia coli . The plasmid was transformed into Rosetta™ (DE3) 
pLysS E. coli strain (Novagen, Madison, WI). Clones were verified by PCR and protein 
expression, and kept at -80°C for further use. Transformed cells were recuperated in LB 
medium containing appropriate antibiotics, and overexpression of BP was done at 37ºC 
using 1mM isopropyl--D-thiogalactopyranoside (IPTG) for 4 hours. After 
overexpression, cells were harvested and lysed via sonication in lysis buffer (20 mM 
imidazole; pH 7.4) with addition of the protease inhibitor cocktail, HALT™ (Thermo 
Scientific, Inc.). The lysed cells were centrifuged, and the supernatant was run through 
affinity purification column using a His60 Ni Superflow resin (Clontech, Mountain 
View, CA) following manufacturer’s recommendations. Following binding of proteins, 
the affinity column was washed with 30ml of wash buffer (40 mM imidazole; pH 7.4). 
Finally, the bound 6×His-tagged proteins was eluted with elution buffer (300 mM 
imidazole; pH 7.4), and the collected protein fractions were aliquoted and stored at -







Purification of BBA34:PepB (BP) construct 
Fractions containing the highest concentration of protein were pooled and 
concentrated using Spin-X™ centrifugal filters (Corning, Lowell, MA) with a 10 kDa 
MWCO. Then, concentrated proteins were passed through a column of Sephadex G-75 
resin for size exclusion chromatography. Pierce™ BCA Protein Assay (Thermo 
Scientific, Inc., Rockford, IL) was used to quantify protein concentration of the collected 
fractions. Then, fractions with relatively high concentration were pooled and centrifuged 
as previously described, and applied to a PD-10 desalting column (GE Healthcare, 
Piscataway, NJ). Collected fractions were analyzed using SDS-12.5% PAGE, and 
fractions with highest concentration of protein were pooled and concentrated using the 
Spin-X centrifugal filters. A 61.5-KDa BBA34:PepB was purified and stored at 4°C 
until further use in animal experiments. 
Expression and purification of control proteins  
Control proteins OspC and BBA34 were previously cloned into pET23a and 
transformed into Rosetta™ (DE3) pLysS Escherichia coli (Novagen, Madison, WI) by 
Dr. Esteve-Gasent, and stored at -80ºC for further use. Transformed cells were 
recuperated in LB medium containing appropriate antibiotics, and overexpression of 
BBA34:PepB was done at 37ºC using 1mM isopropyl--D-thiogalactopyranoside 
(IPTG) for 3 hours. After overexpression, cells were harvested, washed, and sonicated 
for a total sonication time of 10 minutes in lysis buffer (20 mM imidazole; pH 7.4) with 
addition of the protease inhibitor cocktail, HALT™ (Thermo Scientific, Inc., Rockford 




Superflow resin (Clontech, Mountain View, CA), for affinity purification according to 
the manufacturer's protocol. After binding, proteins were washed with 30ml of wash 
buffer (40 mM imidazole; pH 7.4). Finally, 6×His-tagged proteins were eluted with 
elution buffer (300 mM imidazole; pH 7.4), and the collected fractions were then 
analyzed using SDS–PAGE.  
Purification of the control proteins was started with dialysis of the concentrated 
fractions of protein into dialysis buffer (50 mM Sodium Phosphate, 300 mM Sodium 
Chloride, 0.1% Triton X-100; pH 7.4) using Slide-A-Lyzer dialysis cassettes (Thermo 
Scientific, Inc., Rockford, IL). Dialyzed proteins were then concentrated with a 10 kDa 
MWCO (EMD Millipore, Billerica, MA). After that, control proteins were quantified 
using Pierce™ BCA Protein Assay (Thermo Scientific, Inc., Rockford, IL), and then 
were kept at 4°C until further use. 
Immunization 
Six to eight weeks old C3H/HeN mice (n=6 per group) were immunized 
subcutaneously with decreasing antigen dosages of 50µg/mouse for priming followed by 
10µg/mouse at 14-days post-priming, and a final booster dose of 5µg/mouse at 28-days 
post-priming in combination with 5% Adjuplex™ adjuvant (Advanced BioAdjuvants 
LLC). In this study we included the following groups: BP, BBA34, OspC and a naïve 
control group. Eight weeks post-priming blood samples were collected, and specific IgG 






To evaluate protection induced by the scaffolded antigen BP, we infected mice 
(n=6) subcutaneously ten weeks post-priming with a dose of 105 Borrelial cells per 
mouse. First, PCR screening was conducted to detect the presence of essential plasmids 
required for the survival and infection of B. burgdorferi strain that was used in the 
challenge studies. The primers for PCR screening method were previously described 
[283]. Four weeks post-challenge mice were euthanized and blood and tissue samples 
were collected to evaluate protection. The sampled tissues included skin, spleen, 
inguinal lymph nodes, heart, bladder, and tibiotarsal joint. Tissues were cultured in 
BSK-II media complemented with 6% inactivated naïve rabbit serum and incubated at 
32ºC and 1% CO2. The cultures were blindly passed into fresh BSK-II media after 5 
days post-initial inoculation and then incubated at 32ºC and 1% CO2 for up to 21 days. 
The initial and blind passaged cultures were evaluated under dark field microscopy at 14 
and 21 days post-inoculation for bacterial growth [284]. We evaluated bacterial burden 
in skin, spleen, inguinal lymph node, and tibiotarsal joint by qPCR as previously 
described [285].  
Statistical Analysis  
Antibody titers were analyzed with Two-way ANOVA to evaluate the significant 
differences in between the different immunized groups. In quantitative real time PCR 
data, Mann Whitney U test was run to statistically compare in between groups. All 






Plasmid profile of B. burgdorferi 
 The results of PCR screening showed that all essential plasmids were detected in 
the B. burgdorferi B31 strain that was used in challenge protocol to confirm the ability 






Efficacy of BBA34:PepB construct 
In previous studies, Dr. Christina Brock demonstrated that the immunization 
schedule described above was able to induce specific IgG antibodies in immunized 
animals using BBA34:PepB. Furthermore, Dr. Brock demonstrated the presence of 
comparable antibody titers in both BBA34 and BP immunized mice. Hence, in this study 
we evaluated the presence of protective antibodies in the immunized animals. To this 
end, we infected both control and immunized groups with 105 spirochetes/mouse via 
needle inoculation. As shown in Figure 2.2 immunized animals were able to induce high 
Figure 2.1: Plasmid profile of Borrelia burgdorferi B31 strain. PCR screening on 1% 
agarose gel revealed presence of all essential plasmids. Ld: DNA Ladder (LD) weight is 
represented in base pairs (bp) on the left of the image. 1: cp26; 2: lp5; 3: lp17; 4: lp25; 5: 




specific antibody titers 8-weeks post-priming. In addition, all groups developed specific 
antibodies against B. burgdorferi post-challenge. 
 
On the other hand, and as shown in Figure 2.3 immunized mice were not able to 
clear the infection when tissues were inoculated in BSK-II medium and incubated at 
32ºC and 1%CO2. As shown in this figure, even though there is significantly lower 
bacteria recovery from tissues isolated from immunized animals, most tissues were able 
to grow viable bacteria in media, and therefore, we considered that immunized animals 
were not protected.  
                                
       
Figure 2.2: BBA34, BP and OspC induce specific antibodies in immunized C3H/HeN mice. 
(Left diagram) Specific IgG titers in the immunized groups. HA denotes Homologous Antigen; Bb 
denotes Borrelia burgdorferi whole cell lysates; PepB denotes the specific peptide B antigen used as 
coating agents in the ELISA. (Right diagram) anti-Borrelia burgdorferi IgG levels in the different 
















































Furthermore, we evaluated the bacterial burden in the collected tissues by means 
of qPCR. As shown in Figure 2.4, there was significantly low bacterial burden in all 
examined tissues of BBA34:PepB compared with the control group. Interestingly, 
BBA34 and OspC groups generally had lower bacterial load in all tissues compared with 
the control group and the BP group. Taken together, and considering both bacterial 
burden and bacterial recovery from tissues, immunization with BP was not able to clear 
the infection in this experiment, and consequently we did not consider this alternative as 
a potential vaccine formulation in subsequent studies. 
 
 
Figure 2.3. Bacterial recovery. In BSK-II medium complemented with 6% inactivated 
normal rabbit serum and incubated at 32ºC and 1% CO2. In vaccinated groups 1/6 animals 
showed clean tissues. In BBA34:PepB immunized animals 2/6 spleens and 3/6 joints showed 
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Figure 2.4. BBA34:PepB did not confer protection in immunized mice infected with B. 
burgdorferi. Bacterial burden was significantly reduced in mice immunized with BBA34:PepB, 
BBA34, and OspC in all examined tissues including skin (A), spleen (B), lymph nodes (C), and joints 
(D) compared with control group. * Denotes statistical significances (* P value < 0.05; ** P value < 















































































































































































The increasing of geographic distribution and prevalence of LD cases has been 
associated with expanding of public health concern since the disease was identified. 
Vaccination is an effective approach that can be used efficiently to control the LD cases 
in humans and reduce the economic burden of the disease [286]. Many studies have 
evaluated several vaccine candidates against LD including outer surface lipoproteins and 
other antigens [287, 288]. In our studies, PepB has shown promising results as a vaccine 
candidate against LD, providing 50% protective efficacy in tick challenge model when 
the peptide was conjugated to KLH [79].  
Scaffolding molecule BBA34 in conjunction with PepB was used in this study to 
enhance the efficacy of the selected peptide in the murine model of LD. The use of 
scaffold protein BBA34 excludes introducing foreign immunostimulants that might 
induce adverse reactions, when they are tested in a host. Evaluation of immune response 
in immunized mice revealed presence of significant high antibody titers compared to the 
control group, however, PepB specific antibody titer was very low. Therefore, it may be 
revealed that the immune response was not enhanced against the PepB, this might be due 
to the fact that the scaffolding molecule impeded the appropriate exposure of the peptide 
to the immune system. The scaffolding molecule with inserted PepB might require 
additional optimization in order to be effective. This outcome is similar to the study of 
McLellan et al. in which authors showed that the use of scaffolding structure was unable 
to induce antibody response in immunized mice against an antigen derived from 




Bacterial burden in tissues was evaluated to determine a protective efficiency of 
the scaffolded PepB antigen in immunized mice. The BBA34:PepB construct, and the 
BBA34 and OspC proteins showed a reduction in the bacterial load in the examined 
tissues compared with the control group. In addition, viable spirochetes were grown in 
the cultured tissues in BSK-II media from all immunized groups. Hence, the PepB was 
not considered protective in the scaffolding context, and other alternatives could be 
investigated to formulate an efficient PepB–based vaccine candidate. The 12-mer 
peptide (PepB) is unable to induce an immune response by itself, because of its small 
size, therefore it is essential to increase its size to render it immunogenic. The PepB 
design can be further explored in the context of a multiple-copy peptide antigen 
approach. In fact, multiple-copy peptide method has been shown that it stimulated a 
better antibody response than that seen with a single copy peptide conjugated with KLH 
[290].  
In the multiple-copy peptide design the selected antigen is exposed in a well-
defined orientation, and it excludes any unnecessary structural components that may 
include suppressor epitopes that might be found in scaffolding, and/or carrier molecules. 
In addition, a multiple-copy peptide is considered highly immunogenic, and can induce 
both humoral and cellular immune responses against HIV infection in human [291]. 
Furthermore, previous studies showed that a multiple-copy peptide antigen derived from 
the circumsporozoite protein (CSP) of Plasmodium yoelii was able to confer protection 
in mice against malaria infection [292]. Also, other antigen delivery systems can be used 




polymersomes, and immuno-stimulating complexes (ISCOMs) [293-295]. These 
methods can be used to improve antigen persistence, uptake, and presentation, and thus 
able to potentiate immune response effectively. 
In this study, the scaffolding of PepB approach did not provided with promising 
results, and therefore, we did not proceed with it. Hence, other novel methods were 
explored in terms of reformulation of PepB design, and/or conjugation with carrier 
molecules to improve the immunogenicity and protective efficacy of the PepB-based 






EVALUATE PROTECTIVE EFFICACY OF THE CONJUGATED PEPB 
 
Introduction 
Lyme disease (LD) is a vector-borne disease transmitted by hard ticks of genus 
Ixodes spp. The prevalence of B. burgdorferi in infected ticks can reach up to 50% in 
endemic areas [296-298]. Borrelia genus is divided into two major clades, one group of 
species causing Lyme Disease (LD), and the other group causing relapsing fever. As 
mentioned in chapter 1, LD is the most prevalent tick-borne infection in the United 
States with more than 30,000 cases reported annually according to the Centers for 
Disease Control and Prevention (CDC). However, the CDC estimates that only 10% of 
all LD cases are actually reported, and thus, the actual infected cases will be closer to 
300,000 per year [299, 300]. LD infection is transmitted to human and other animals via 
the bite of an infected tick, and with the geographical expansion of tick population in 
recent decades, primarily due to climate change, the risk for human infection is increased 
in the newly established tick habitats [301-303]. These events have been associated with 
a steadily increased numbers of notifiable tick-borne diseases, as well as the 
identification of new arthropod-borne pathogens such as Borrelia mayonii and B. 
hermsii [304].  
Currently, there is no available vaccine against LD in humans, in addition, 
control measures are based on preventive exposure of individuals to infected ticks by 




LYMErix (SmithKline Beecham) was the only available OspA-based vaccine for human 
use in the US, but it was withdrawn from the market in 2002. Hence, researchers focus 
their efforts to develop potential vaccine candidates against LD in human, using a 
number of different antigens such as OspA, OspB, OspC, decorin binding protein A 
(DbpA), BBK32, and RevA [305-307]. To date, several attempts have been made to 
generate a protective vaccine for use in humans. Nonetheless, they have been considered 
ineffective to confer protection against LD caused by various genospecies of spirochetes, 
due to high heterogeneity observed in such antigens within different serotypes of 
spirochetes.  
Historically, the development of a LD vaccine has been based on modifications 
of either the outer surface protein A (OspA) or C (OspC). In fact, LYMErix by 
SmithKline Beecham, the first and only LD vaccine licensed for human use, was an 
OspA vaccine [69]. It was withdrawn from the market in 2002 due to lack of interest and 
potential side effects associated with using LYMErix. This vaccine formulation targeted 
the Borrelial OspA lipoprotein, which is expressed when the pathogen is in the arthropod 
tick vector. When expressed, OspA mediates the attachment of spirochetes to the tick 
mid-gut via its receptor (TROSPA) [144]. Homologs of TROSPA have been identified 
not only in Ixodes scapularis (vector of B. burgdorferi in the US), but also in I. ricinus, 
the tick species transmitting the infection in Europe [25], and I. persulcatus, the species 
transmitting Borrelia in Asia [26].  
During tick feeding B. burgdorferi migrated to the salivary glands of ticks, and 




upon blood intake by the tick [22, 144]. Thus, OspA based vaccines are effective in 
conferring protective immunity by blocking the transmission of B. burgdorferi from the 
tick to the mammalian host [145]. In fact, the antibodies induced by the OspA vaccine 
neutralizes B. burgdorferi in the tick vector rather than in mammalian host. Furthermore, 
administration of OspA formulated vaccine to small rodents (reservoir hosts) has been 
used to reduce the prevalence of B. burgdorferi in the mammalian reservoirs and the tick 
vectors, and break the enzootic cycle of the disease in nature, that might reduce the 
incidence of B. burgdorferi infection in human [146, 147]. In addition, in veterinary 
medicine, multiple OspA based vaccines have been used to immunize dogs against LD, 
such as (Nobivac® Lyme by Merck Animal Health, Merck & Co. Inc.; LymeVax® from 
Zoetis and Recombitek® Lyme from Merial Inc.) [75, 148]. Nevertheless, to have an 
effective vaccine, specific antibodies have to neutralize B. burgdorferi while in the tick 
vector. Hence, individuals immunized with OspA vaccines need to maintain high 
antibody titers to be protected at all times, and thus, this can be one of the major 
drawbacks associated with using OspA-based vaccine.  
The other important differentially expressed protein is the outer surface protein C 
(OspC). As described in Chapter 1, this lipoprotein is expressed during mammalian 
infection and it facilitates transmission of Borrelia burgdorferi sensu lato (s.l.) from the 
tick vector to the mammalian hosts [70]. Furthermore, OspC shows significant 
heterogeneity within B. burgdorferi s.l. isolates [153]. Therefore, in order to use a 
protective vaccine, any construct of OspC based vaccine is required to incorporate the 




fact, to generate a complete and broadly protective vaccine against LD using the OspC 
antigen, it would require the use of 34 distinct epitopes [154]. Based on such 
observations, an octavalent and chimeric OspC vaccine candidate has been evaluated 
[155], and a recombinant, heptavalent LD vaccine has been developed by Zoetis 
Services LLC, VANGUARD® crLyme, formulated to prevent LD in dogs [156].  
In our laboratory, vaccine studies showed promising results when using a short 
peptide (PepB), derived from a highly conserved protein (BB0172) present on the outer 
membrane of B. burgdorferi s.l. [51]. Basically, BB0172 is an extracellular exposed 
proteins, that binds to the human integrin α3β1, via its von Willebrand factor A (vWFA) 
domain [51]. It is expressed only when the growth conditions of B. burgdorferi cultures 
are shifting from the room temperature pH of 7.6 (unfed tick conditions) to 37ºC pH 6.8 
(fed tick conditions). In addition, B. burgdorferi is not expressing BB0172 in cultures 
adapted to either conditions. Furthermore, BB0172 is not detected by serum from 
infected animals; therefore, this formulation will be beneficial in differentiating infected 
animals from vaccinated ones (DIVA). Moreover, BB0172 is highly conserved among 
the different genotypes within the B. burgdorferi sensu lato complex present in the US 
and Europe. In an previous study, Small and collaborators [79] showed that the BB0172 
derived peptide B (PepB) conjugated to the Keyhole Limpet Hemocyanin (KLH) hapten, 
confer protection in the murine model of LD. BB0172 is a chromosomally encoded 
membrane protein, that is highly conserved among pathogenic Borrelia spp. Even 
though PepB was able to induce high specific antibody titers in immunized animals and 




high dose challenge with 105 spirochetes/mouse, and was partially protective when using 
the tick model of infection.  
Taking together, in our study the BB0172 derived peptide PepB was conjugated 
to carrier molecules, which include cross reactive-material 197 (CRM197) and Tetanus 
Toxoid heavy chain (TTHc), with the objective to further improve its immunogenicity 
and long-term protection. As described in Chapter 1, the carrier proteins selected for this 
study, have been successfully used in conjugate vaccine to immunize millions of people 
around the globe. Of these, CRM197 and TTHc are common carrier proteins used 
mainly in Glycoconjugate vaccines [223], and also used in conjugation with peptide 
antigens such as Improvest® product (Pfizer Animal Health) [308]. The extensive body 
of information about their immunogenicity and safety profile in clinical use is well-
known [309].  
Overall, in the current study, the BB0172 derived peptide PepB was conjugated 
to carrier proteins including TTHc and CRM197. We immunized C3H/HeN mice with 
these antigens following prime-boost immunization protocol. The aim of our study is to 
evaluate the safety and protective efficacy of conjugated PepB formulations in the 





Materials and methods 
Ethics statement 
All animal related procedures were approved by the Institutional Animal Care 
and Use Committee (IACUC) at Texas A&M University, Animal Use Protocol number 
2017-0022. The mice were kept in Texas A&M University animal facility accredited by 
the Association for Assessment and Accreditation of Laboratory Animal Care 
(AAALAC).  
Peptide design and conjugation 
The selected antigen, a short peptide (Pep B) derived from the Borrelial outer 
membrane protein BB0172 was synthetized by Peptide 2.0 (Chantilly, VA) at a 95-98% 
purity. After synthesis, Pep B was conjugated to commercially available carrier 
molecules TTHc and CRM197. The conjugation process was done in collaboration with 
Fina Biosolutions LLC (Rockville, MD). In addition, Pep B conjugated to Bovine Serum 
Albumin (BSA) was generated to evaluate antibody levels against PepB in traditional 
Enzyme Linked Immunosorbent Assays (ELISA). 
Borrelia burgdorferi strains and growing conditions 
Borrelia burgdorferi B31 A3 virulent strain was used in this study. The bacteria 
were grown at room temperature (RT) on BSK-II media pH 7.6 complemented with 6% 
inactivated rabbit serum (iNRS), to mimic the unfed tick conditions. The culture was 




in BSK-II medium pH 6.8 plus 6% iNRS at 37ºC and 1% CO2 in order to mimic the fed 
tick conditions. Cultures were ready when they reached a cell density of 3 to 5×107 
spirochetes/ml. To prepare whole cell lysates antigen for ELISA, cells were harvested, 
washed three times with HBSS buffer (HyClone, Thermo Scientific Inc.), counted, and 
lysed using 0.1mm glass beads on a BeadRuptor 24 (Omni International, Inc.) at 5,000 
rpm for 5 minutes. Lysates were stored at -20ºC until use to coat ELISA plates. For the 
needle infection experiment, Bb cultures were prepared as above. The bacterial cultures 
were shifted from RT/pH 7.6 to 32ºC/pH 6.8 and incubated until the cell density reached 
3-5×107 spirochetes/ml. Then, the bacteria were harvested, washed twice with HBSS 
buffer, and resuspended in HBSS buffer with inactivated naïve rabbit serum (50:50, v:v). 
Cell suspensions were quantified and adjusted to the required infective dose. 
Immunization protocol 
Six to eight week old female C3H/HeN mice were divided into four groups with 
9 mice each. Two groups of mice served as control groups receiving the unconjugated 
carrier molecules, Cross Reacting Material 197 (CRM197) for group 1 and Tetanus 
Toxoid heavy chain (TTHc) for group 2. The other two groups received conjugated 
peptide, CRM197:PepB and TTHc:PepB, groups 3 and 4 respectively. All groups were 
primed at 50μg of the antigen subcutaneously per animal with their respective antigen. 
Animals were boosted with 10 and 5 μg/animal subcutaneously at days 14 and 28 post-
priming. All vaccine formulations were prepared in 5% Adjuplex™ (v:v, Sigma-Aldrich, 
St. Louis, MO). On week 8 post-priming, blood was collected from all groups to detect 




euthanized and samples from skin, heart, liver, kidney, and tibiotarsal joint were 
collected to evaluate histopathological signs post-immunization. On week 12 post-
priming, mice were challenged with pathogenic B. burgdorferi via subcutaneous 
inoculation.  
B. burgdorferi challenge protocol 
To evaluate protective efficacy of the formulated antigen, immunized mice (n=6) 
were challenged 12 weeks post-priming by administering an infectious dose of 105 B. 
burgdorferi/mouse (1000× the infectious dose 50 (ID50)) subcutaneously in HBSS 
containing inactivated rabbit serum (v:v, 50:50). Three weeks post-challenge, mice were 
euthanized and blood and tissue samples were collected from each mouse. The sampled 
tissues included skin, spleen, inguinal lymph nodes, heart, bladder, and tibiotarsal joint. 
Tissues were cultured in BSK-II media complemented with 6% inactivated naïve rabbit 
serum and incubated at 32ºC and 1% CO2. The cultures were blindly passed into fresh 
BSK-II media after 5 days post initial inoculation and then incubated at 32ºC and 1% 
CO2 for up to 21 days. The initial and blind passaged cultures were evaluated under dark 
field microscopy at 14 and 21 days post-inoculation for bacterial growth [284]. We 
evaluated bacterial burden in skin, spleen, inguinal lymph node, and tibiotarsal joint by 
qPCR as previously described [285]. Finally, parts of skin, heart, liver, kidney, and 







Tissues were collected from immunized mice on week 8 post-priming, and 3 
weeks after challenge. After that, they were preserved in 10% formalin, while tibiotarsal 
joints were decalcified in 10% EDTA for 4 weeks prior to further processing. All tissues 
were histologically processed and stained with H&E. The histopathologic changes in 
post-immunized and infected tissues were evaluated by a board-certified pathologist, and 
inflammation in selected tissues was scored from 0 – 4. Inflammation scores were 
chosen based on the severity of inflammation, starting from normal = 0 (no 
inflammation), minimal = 1 (one small foci of inflammation), mild = 2 (2-5 foci of 
inflammation with increased numbers of inflammatory cells), moderate = 3 (multifocal 
inflammation with significant number of inflammatory cells), and severe = 4 (multifocal 
to diffuse, with more than 30% of section infiltrated with inflammatory cells) [310]. 
Enzyme-linked Immunosorbent Assay 
The enzyme-linked immunosorbent assay (ELISA) was used to evaluate IgG and 
IgM titers in serum samples from immunized animals, and from immunized and infected 
animals. In brief, 96 well Nunc Maxisorb® plates (Thermo Scientific, Ltd.) were coated 
overnight at 4ºC with Peptide B conjugated to Bovine Serum Albumin (BSA; Fina 
Biosolutions Inc. (Rockville, MD)) at a concentration of 100 ng/well. To evaluate 
antibody response to borrelial whole cell lysate, B. burgdorferi A3 strain shifted from 
RT/pH 7.6 to 37ºC/pH 6.8 as described above, was used to coat the plates at a cell 
density of 107 Borrelia cells/well. After coating with carbonate buffer pH 9.6, plates 




Tween 20, (PBS–T)) and blocked with blocking buffer (PBS–T containing 3% BSA) for 
1 hour at room temperature. Following three washes with PBS–T, mice sera were loaded 
to the wells in 2-fold serial dilutions in dilution buffer (PBS–T containing 1% BSA) in 
duplicate across the plate ranging from 1:100 to 1:102,400. Plates were incubated for 1 
hour at room temperature, followed by three washes with PBS–T. Plates were 
subsequently incubated with secondary conjugated anti–mouse antibody (Horseradish 
Peroxidase, HRP) diluted 1:3,000 in dilution buffer. After washing, plates were 
developed using the substrate o-Phenylenediamine dihydrochloride (OPD) (Pierce, 
Thermo Scientific, Ltd), and read at the optical density (OD) of 450 nm by using the 
Bio-Tek Synergy™ H1 microplate reader and Gen5™ software (BioTek Instruments 
Inc., Winooski, VT).  
Quantitative measurement of tissue spirochetes 
To evaluate bacterial burden of spirochetes in infected mice, qPCR was 
performed. To this end, DNA was isolated from collected tissues (skin, spleen, lymph 
node and tibiotarsal joint) using the High Pure PCR Template Preparation Kit (Roche 
Applied Science, Indianapolis, IN). After measuring quality of DNA, to evaluate the 
presence of B. burgdorferi, the flagellin B (flaB) gene was amplified as previously 
described [311]. For reference, the murine β-actin gene was utilized for each sample. 
Final results were reported as flaB copies per 106 copies β-actin. All primers and 







Serum samples collected as described above (8 weeks post-priming) were used to 
evaluate whether immunized animals generated borrelicidal antibodies. To this end, B. 
burgdorferi was shifted from RT/pH 7.6 to 32ºC/pH 6.8 and cultured in the presence of 
1% CO2 to induce expression of BB0172 protein. After the cell density reached 2–5×107 
Bb/ml, the culture was washed twice with HBSS buffer, and finally resuspended in 
BSK-II media with HBSS buffer (50:50, v:v). B. burgdorferi cells (106/well) were 
incubated with serial dilutions of sera from naïve and immunized animals in a 96-well 
plate for 1hr at 37ºC, followed by the addition of 1:10 dilution of commercially available 
rabbit complement (Sigma-Aldrich). The mixtures were incubated for an additional 1hr 
at 37ºC. Borrelial survival was measured before and after the addition of rabbit 
complement by doing 10-fold serial dilutions in fresh BSK-II media, and incubating the 
cells at 32ºC and 1% CO2. Bacteria growth was evaluated under dark field microscopy at 
48 and 72 hours.  
Statistical Analysis  
Antibody titers and presence of bactericidal antibodies were analyzed with Two-
way ANOVA to evaluate the significant differences in between the diverse immunized 
groups. In quantitative real time PCR data, Kruskal-Wallis test was run to statistically 
compare between groups. All graphs and analysis were done using Prism 7.0 (GraphPad 






Efficacy of PepB conjugated vaccine candidate 
Mice were immunized with conjugated peptide CRM197-PepB and TTHc-PepB 
according to previously described protocols [79]. In order to evaluate humoral immune 
response of immunized mice, sera from 3 animals of each group were collected at 8 
weeks post-priming. To detect IgG and IgM titers, the PepB antigen was used to coat the 
ELISA plates. As shown in Figure 3.1, high IgG titers (100,000) were observed in all 3 
animals immunized with conjugated PepB vaccines, compared to low titer of (100) in 
both carrier molecule immunized animals (CRM197 and TTHc groups). In regards to 
IgM levels, they were present at low titer (100) in all 3 animals in all conjugated PepB 






Figure 3.1. Peptide B specific antibodies. High IgG titers were detected at 8–weeks post–priming, 
while IgM titers of immunized animals were low at basal levels. * Denotes statistical significances 




The immune response of animals after challenge via subcutaneous needle 
inoculation with 105 spirochetes/mouse (1000×ID50) was detected by tracking antibody 
titers in the serum samples which were collected at 3–weeks post–challenge. As shown 
in Figure 3.2A, ELISA plates coated with Pep B antigen showed significant high IgG 
titers around (1:10,000) in all immunized animals with conjugated PepB compared to the 
results observed in animals receiving the unconjugated CRM197 and TTHc, which were 
at basal levels (1:100). We used whole Borrelia lysate antigen to evaluate the 
development of anti-Borrelia antibodies post–challenge (Figure 3.2.B). ELISA results of 
IgG titer were generally high at around (1:10,000) in all immunized and infected animal 




(A)      (B) 
                          
Figure 3.2. High IgG antibody titers were detected in immunized and infected mice against 
peptide B and Borrelia burgdorferi at 3 weeks post needle infection. TTHc:PepB and 
CRM197:PepB induced significant high anti-PepB IgG titers compared with TTHc and CRM197 
(A). The presence of high anti-Borrelia IgG titers in all animal groups (B). * Denotes statistical 




Evaluation of protective efficacy of the conjugated Pep B includes recovery of 
Lyme spirochetes from collected tissues of immunized animals post-challenge. 
Immunized C3H/HeN mice were infected at 12-weeks post-priming with subcutaneous 
inoculation of 105 spirochetes/mouse. Mice were euthanized at 4-weeks post-challenge, 
and bacterial burden in animal tissues including skin, spleen, lymph node, and tibiotarsal 
joints was determined by qPCR to evaluate protection in immunized animals. 
TTHc:PepB group showed significant reduction of spirochetes load in skin, lymph 
nodes, and joints compared to the TTHc group, which had high copy numbers of flaB 
(Figure 3.3). The experiment of immunizing mice with TTHc:PepB was repeated to 
confirm the observed results. As shown in Figure 3.4, the bacterial burden was 
significantly reduced in skin and spleen in TTHc:PepB immunized animals. However, in 
animals receiving the CRM197:PepB antigen, the spirochete load was relatively low 
compared to the CRM197 group in lymph nodes, and joints, but the significant reduction 
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Figure 3.3. TTHc:PepB conferred protection in immunized mice infected with B. burgdorferi. 
Bacterial burden was significantly reduced in mice immunized with TTHc:PepB in all examined 
tissues including skin (A) lymph nodes (C), and joints (D) when compared with TTHc immunized 
animals. CRM197:PepB showed reduction in bacterial load, but it was only significant reduction in 
skin (A) when compared to CRM197. * Denotes statistical significances (* P value < 0.05; ** P 








Figure 3.4. TTHc:PepB protection was replicated in a second experiment. Bacterial burden was 
significantly reduced in mice immunized with TTHc:PepB in some of the collected tissues including 
skin (A) and spleen (B) compared with TTHc. * Denotes statistical significances (* P value < 0.05; 






Similarly, bacterial recovery was evaluated in different tissues by growth in 
BSK-II medium. Borrelia burgdorferi was recovered in culture from 2 out of 7 mice 
immunized with TTHc:PepB group, whereas B. burgdorferi was recovered from all 
tissues of all other immunized animals except in CRM197:PepB group, while B. 
burgdorferi was recovered only from 4 out of 6 cultures from skin sample (Table 3.1). In 
regard to TTHc: PepB group, this experiment was repeated to confirm our results, and it 
shown that B. burgdorferi was recovered in all sampled cultures only from 2 out of 5 
mice (Table 3.2). Therefore, overall it was estimated that TTHc:PepB conferred 66% 









Table 3.1. Recovery of B. burgdorferi from sampled tissues of immunized mice at 3 weeks 
post needle infection (Biological replica 1) 
Group/  
105  spirochetes/mouse      
Skin Lymph 
Node 
Spleen Bladder Heart Joint Total 
CRM197 6/6 6/6 6/6 6/6 6/6 6/6 36/36 
CRM197:PepB 4/6 6/6 6/6 6/6 6/6 6/6 34/36 
TTHc 6/6 6/6 6/6 6/6 6/6 6/6 36/36 





Evaluation of IgG isotypes to determine whether Th1 and /or Th2 immune 
response was induced in immunized animals, conjugated PepB groups, post-infection 
with B. burgdorferi, showed significant increase in IgG1 titers compared to the TTHc 
and CRM197 groups. Also, IgG2a titers showed the same trend as IgG1 (Figure 3.5). 
 
Evaluate safety of administered antigens 
The safety of TTHc:PepB and CRM197:PepB in immunized animals was 
evaluated at 8-weeks post-priming by histopathology. These antigens are considered safe 
when they are not inducing inflammation or other micro or macroscopical tissue damage 
post-inoculation. Conjugated PepB groups including CRM197:PepB and TTHc:PepB 
showed a slight inflammatory response in spleen, liver and joint, that seem to be 
correlated with protection against infection, principally in the TTHc:PepB immunized 
group. Overall, our experiments did not reveal significant inflammation in either group 
after immunization (Figure 3.6). 
 
Table 3.2. Recovery of B. burgdorferi from sampled tissues of immunized mice at 3 weeks 
post needle infection (Biological replica 2) 
Group/  
105  spirochetes/mouse 
Skin Lymph 
Node 
Spleen Bladder Heart Joint Total 
TTHc 3/3 3/3 3/3 3/3 3/3 3/3 18/18 







Figure 3.5. IgG1 and IgG2a antibody titers at 3 weeks post needle infection. * Denotes 
statistical significances (* P value < 0.05; ** P value < 0.01; *** P value < 0.001) when compared 
with control groups. Letter denotes statistical significance when comparing IgG1 and IgG2 levels 































Figure 3.6. Histopathological changes score in immunized animals at 8 weeks post-priming. * 


















































Evaluate the serum bactericidal assay of immunized mice 
The serum bactericidal assay was measured in sera of immunized mice using 
commercially available rabbit complement (Sigma-Aldrich). The antibodies from 
immunized sera in both constructs CRM197:PepB and TTHc:PepB were effective in 
reducing the number of B. burgdorferi cells at all tested serum dilutions, including (1:50, 
1:100, 1:1000, and 1:2000). It was obvious that sera from the immunized mice with 
CRM197:PepB and TTHc:PepB constructs showed a significant reduction in borrelial 





Figure 3.7. Anti-PepB antibodies are Borrelicidal. B. burgdorferi cells (106/ml) were incubated 
with serial dilutions of sera from naïve and immunized animals in a 96-well plate for 1hr at 37ºC, 
followed by the addition of 1:10 dilution of commercially available rabbit complement. The mixture 
was incubated for an additional 1hr at 37ºC. Borrelial survival was measured before and after the 
addition of rabbit complement by doing 10-fold serial dilutions in fresh BSK-II media, and 
incubating at 37ºC and 1% CO2. Bacteria growth was evaluated under dark field microscopy at 72 
hours. Negative indicates no addition of immunized serum. 1:10, 1:25, 1:50 and 1:100 represent 
dilutions of the serum added. * Denotes statistical significance: (** P value < 0.01; **** P value < 
0.0001). Letters denote statistical significance when comparing control groups with their 



















































Investigations into alternative antigens for LD vaccine in humans have been 
considered by researchers, since there is currently no availability for such vaccine in the 
markets. Many antigens have been tested as vaccine candidates to control LD infection 
[313]. However, most studies have been focused on outer surface proteins such as OspA 
and OspC [72, 75]. In addition, there are other few novel antigens that have been used as 
vaccine candidates such as Decorin-binding protein A (DbpA) [314, 315], and BBA52 
[316]. Our team have previously identified BB0172, a chromosomally encoded protein, 
which is extracellularly exposed, that binds to the human integrin α3β1, via its von 
Willebrand factor A (vWFA) domain [51]. Also, BB0172 derived peptide has been 
successfully used by our team as a vaccine candidate that was able to confer protection 
in mice challenged by needle inoculation with low doses of borrelial cells (10× ID50) 
[79]. 
In this study, we explored the protective efficacy of the conjugated PepB 
following subcutaneous inoculation with 105 spirochetes/mouse, in which TTHc:PepB 
had the highest protective efficacy (66%) in immunized mice compared to 
CRM197:PepB immunized group. Based on the previous study [79], we sampled 3 
animals from each group to evaluate antibody titers, and histopathological changes at 8-
weeks post-priming. The humoral immune response is predominantly demonstrated to be 
responsible for protection against infection with B. burgdorferi [317-319]. Serum 
bactericidal assay (SBA) is mediated by antibody and complement reactions that lead to 




[320]. In our study, we showed that conjugated peptide B was able to elicit production of 
borrelicidal antibodies. These findings are supported by other studies that showed the 
carrier proteins TTHc and CRM197 are used with licensed conjugate meningococcal 
vaccines in Europe, and they have shown to induce robust bactericidal antibodies [320-
322]. Such antibodies were able to confer protection against septicemia and meningitis 
caused by different strains of Neisseria meningitis [323]. However, in these previous 
studies, the immune response was slightly skewed toward a Th1. In contrast, in our 
current study, the conjugated pepB formulations were able to elicit a mixed Th1/Th2 
immune response, as determined by elevated IgG1 and IgG2a titers in immunized mice 
after needle infection. Based on previous publications, the predominance of Th1 immune 
response is important to control LD spirochetes in mice and humans [324-327]. 
In general, peptides have limited stimulation of B or T cells repertoire since they 
are small in size [328]. Therefore, different approaches have been implemented to 
improve peptides’ efficacy such as novel folding strategies that are used to mimic the 
native structure of the selected epitopes [329], and other approaches that include, but not 
limited to, the use of scaffolding molecules, incorporation of additional 
immunostimulatory molecules, and the use of carrier proteins [330-332]. Of these 
strategies, the use of carrier molecules has been quite successful. In particular, the 
tetanus toxoid (TT) has been used extensively. Structurally, TT is composed of the light 
chain (LC) (catalytic domain), and the heavy chain (HC) (binding domain). The latter 
contains two functional domains; an amino-terminal portion (HN) and a carboxy-terminal 




responsible for LC translocation in the cytosol [333]. Tetanus toxin is a potent 
neurotoxin produced by anaerobic bacteria of Clostridium tetani, and it can be 
chemically detoxified to tetanus toxoid. This is used as a vaccine against the tetanus 
disease, and also as a carrier protein in conjugate vaccines [334]. We included TTHc in 
this study since it is commercially available, and its precursor (TT) has already been 
licensed and in the market. The immunogenicity of TT is attributed to the HC domain, 
which is the principle component of TT molecule, as the toxin neutralizing epitopes are 
located within that domain [335, 336]. Furthermore, it contains potent T-cell universal 
epitopes, and the HC domain is also responsible for binding and trafficking properties of 
TT [337, 338]. In fact, the immunogenicity of the HC domain of TT was indicated when 
the recombinant form of that domain was able to confer protection in mice following 
challenge with tetanus toxin [339]. It has been shown that immunization of mice with 
OSP:rTTHc was able to produce bactericidal antibodies against Vibrio cholerae [340]. 
In addition, the TTHC has been shown to activate specific CD4+T cells including TH1 
cells [341, 342]. Taken together, synthetic peptides are considered a promising approach 
for the development of potential novel vaccines for an array of infectious diseases [343]. 
They also provide safe and cost-effective method that can be used alternatively to the 
conventional vaccine platforms [344]. 
In our study, the immune response showed a slight increase of IgG2a titers 
compared to IgG1 isotype in immunized mice at 3 weeks post-infection. That trend 
might enhance the efficacy of the conjugated PepB formulation to protect the immunized 




protection in immunized mice, through the evaluation of bacterial recovery from 
different animal tissues. Part of that mechanism might be attributed to the fact that 
murine IgG2a isotype was found to be more effective in serum bactericidal assay (SBA) 
than IgG1 isotype, when they were tested against Neisseria meningitidis strain. 
Furthermore, in the same study, it was shown that IgG2a was more efficient in 
opsonophagocytosis (OP) assay than IgG1 [345].   
In addition, the difference in protective efficacy between the conjugated carriers 
in our study could be related to different number of PepB molecules loaded in each 
carrier molecule. In particular, each molecule of TTHc was conjugated to 12 PepB 
molecules, whereas CRM197 was only conjugated to 9 peptides. This explanation could 
be supported by studies that illustrated that hapten density in a carrier protein is a key 
factor for the induction of a protective immune response [346-349]. In addition, a hapten 
density also has an effect on the selectivity and breadth of the induced antibody 
repertoire, as it has been found that high hapten density in a conjugate was able to 
produce broader spectrum antibodies than low hapten density construct [350]. Moreover, 
when developing meningococcal C conjugated vaccines, it was concluded that TT had 
superior immunogenicity in GCMP-TT compared to GCMP-CRM197 vaccine [351, 
352]. Also, TT has more thermal stability than CRM197, and it was found to retain its 
immunogenicity following exposure to high temperatures [353].  
After needle challenge with B. burgdorferi, TTHc:PepB showed around 66% 
protective efficacy in immunized mice, whereas CRM197:PepB was not protective. 




can be used for further studies. Thus, the current results suggest that TTHc:PepB is the 
most efficacious vaccine candidate and we proceeded with that conjugated pepB 
formulation to challenge immunized mice with the tick model of infection (discussed in 
the next chapter). 
Taken together, our studies demonstrate that TTHc:PepB construct showed a 
high protective efficacy against B. burgdorferi infection compared to the other 
formulation. Thus, it is a promising vaccine candidate that will play a major role in the 
control of Lyme disease, with important DIVA feature (differentiate between infected 







PROTECTION INDUCED BY TTHC:PEPB IN MICE USING THE NATURAL 
ROUTE OF INFECTION  
 
Introduction 
As mentioned in previous chapter, there is no vaccine available against LD for 
use in humans. Hence, prevention of LD relies upon control measures that limit exposure 
to potentially infected ticks, such as the wearing of long sleeves and pants, the avoidance 
of tick-infested areas, and the use of insect repellents. 
Generally, Borrelia species lack classical virulence factors, instead they have the 
ability to survive within the infected hosts and evade their immune response by 
alterations in their outer surface proteins [354]. These spirochetes are also unable to 
synthesize many of essential amino acids, nucleotides and fatty acids needs due to lack 
of major biosynthetic pathways. Therefore, they rely on their vertebrate host and tick 
vector to meet their nutritional requirements [355, 356]. The changes in gene expression 
of spirochetes is the key role for their survival in two disparate environments, the tick 
vector and vertebrate host [357].  
The outer surface proteins of Borrelia burgdorferi have been extensively targeted 
in vaccine studies especially OspA and OspC lipoproteins. These antigens are surface 
exposed and they have been shown to be immunogenic and can induce protective 
antibody responses [208, 358]. In addition, OspA and OspC have acquired the most 




identified. Historically, the OspA based vaccine LYMErixTM was the only product that 
was licensed by the FDA, and distributed in the U.S. markets. However, in response to 
lack of public interest and associated side effects, it was withdrawn from the market in 
2002.   
Reverse vaccinology has enabled researchers to synthesize and test different 
potential vaccine candidates to induce protective immunity [359]. It provides 
information regarding the identification of surface-exposed antigens (epitopes) that can 
be tested in either in vitro or in vivo models to effectively screen these new candidates 
[360]. It is also a useful tool for recognizing novel vaccine candidates through the 
genome analyses of different isolates within the same species or between closely-related 
species [361, 362]. Through this technology, our team has identified a short peptide 
(PepB) that induced a protective immunity in mice against infection with B. burgdorferi 
[79]. PepB is derived from a highly conserved protein (BB0172), which is exposed 
extracellularly, and binds to the human integrin α3β1 at its von Willebrand factor A 
(vWFA) domain. This protein is expressed when the growth conditions of B. burgdorferi 
cultures are shifted from a pH of 7.6 at room temperature (unfed tick conditions) to a pH 
of 6.8 at 37ºC (fed tick conditions). However, B. burgdorferi in cultures adapted to either 
condition do not express BB0172 [51]. In addition, BB0172-derived peptide has not 
been detected by serum in infected animals, making it potentially useful for 
differentiating infected animals from vaccinated ones (DIVA) [79]. Furthermore, among 
the different genotypes in the B. burgdorferi sensu lato complex found in the US and 




KLH:PepB conjugated antigen offered effective protection in the murine model 
of LD at low doses. However, when challenging animals using a high infective dose (105 
spirochetes per mouse), this vaccine candidate failed to be protective. To improve its 
immunogenicity and capacity for long-term protection, in Chapter III, we conjugated 
PepB to carrier molecules, including TTHc and CRM197. Millions of people around the 
globe have been immunized with conjugate vaccines that make use of carrier proteins. 
The two most common carrier proteins used in glycoconjugate vaccines are Cross-
Reacting-Material-197 (CRM197) and tetanus toxoid heavy chain (TTHc). Furthermore, 
information about the immunogenicity and safety profile of carrier proteins in clinical 
use is widely available [309]. 
Generally, ticks are responsible for approximately 95% of the vector-borne 
diseases reported annually in the US [10]. Also, they are second only to mosquitoes as 
vectors of disease-causative agents in humans, and other animal species [363]. In the 
United States, LD is commonly present in the northeastern and upper midwestern states. 
The disease is transmitted by tick bites of Ixodes scapularis and Ixodes pacificus species 
in the eastern and western states respectively [9, 364]. In fact, ticks of the Ixodes genus 
are the main vectors for Lyme borreliosis infection. In the past decades potentially due to 
climate change, tick populations have been extending geographically to other areas 
especially in the north-central and northeastern states, and that might enhance the spread 
of Borrelia infection to other susceptible hosts [365].  
The Ixodes ticks are considered three host ticks with four life stages, starting 




three years to complete according to the environmental factors [366]. The cycle of 
pathogen transmission begins when uninfected ticks acquired the infection after feeding 
on an infected host. Of these hosts, the white-footed mouse (Peromyscus leucopus) is 
considered the most competent reservoir host for B. burgdorferi [202, 367]. In ticks, B. 
burgdorferi infection is transtadially maintained through the tick life stages. Therefore, 
after molting the next tick stage are able to transmit LD to naïve hosts. Consequently, 
ticks are important epidemiological factor in the distribution of the LD [368].  
During a blood meal, B. burgdorferi can be transmitted by Ixodes ticks to the 
vertebrate hosts. Ticks need to take blood meal to complete their development and life 
cycle, as obligate blood feeding ectoparasites. During feeding, ticks usually inject 
salivary proteins at the bite-site to assist in the tick feeding process and also transmission 
of pathogens. In fact, Ixodid tick saliva play a major role in reducing inflammatory 
reactions against vector-borne pathogens [369]. Different pathogens can utilize tick 
salivary molecules to promote their survival and multiplication within the vector, as well 
as transmission to the hosts [370-372]. Tick salivary molecules have anti-hemostatic, 
anti-inflammatory, and immunomodulatory functions that mediate transmission and 
establishment of pathogens in the hosts [32, 373, 374]. For instance, the salivary protein 
Salp15 facilitates B. burgdorferi transmission and replication in the hosts by inhibiting 
complement mediated killing, and also suppressing CD4 (+) T cell responses [35, 36]. 
Thus, it is imperative to test protection induced by novel vaccine candidates using the 
tick model of infection, since there could be different outcomes in the evaluation of 




Materials and methods 
Ethics statement  
All animal experiments and related procedures were followed the animal use 
protocol (AUP #2017-0022) that was approved by the Institutional Animal Care and Use 
Committee of Texas A&M University. Mice were kept and taken care of in an animal 
facility accredited by the Association for the Assessment and Accreditation of 
Laboratory Animal Care, International (AAALAC).  
Growth conditions of Borrelia burgdorferi  
Borrelia burgdorferi B31 A3 strain was used throughout this study. It was grown 
in BSK II media supplemented with 6% inactivated naive rabbit serum (iNRS) and pH 
7.6 under incubation conditions of 1% CO2 and 32°C. Once the culture reached a cell 
density of 2×107 spirochetes/ml, the culture was used to infect naïve nymphs of Ixodes 
scapularis that were used to challenge the immunized animals. 
Antigen administration and immunization protocol 
Based on the results described in Chapter III, TTHc:PepB was the only vaccine 
candidate that was able to protect immunized mice from infection at high infective 
doses. Therefore, in this chapter we will be using TTHc:PepB as the only vaccine 
candidate to test, using the tick model of infection. To this end, and as described in 
Chapter III, groups of 6-8 week old C3H/HeN mice (n=8) were immunized with either 
TTHc, or TTHc:PepB at 0, 2 and 4 weeks. The mice were primed subcutaneously with 




of mice was followed by two boosting doses at 14- and 28-days post-priming, in which 
mice received 10µg/mouse and 5µg/mouse of antigen respectively. A group of 4 mice 
served as the negative controls receiving 10% Adjuplex® adjuvant in saline. To evaluate 
protection, animals were challenged with B. burgdorferi using the tick model of 
infection at either 8-weeks post-priming (high specific IgG in serum) or 12-weeks post-
priming (low specific IgG in serum).  
Infection of Ixodes scapularis nymphs with B. burgdorferi  
Naive nymphs of I. scapularis were purchased from Oklahoma State University 
Tick Laboratory, and were kept in perforated screw cap tubes in an environmental 
chamber at 25ºC, a relative humidity (RH) of 95% and a light/dark cycle of 9hrs/15hr. 
Prior to infection by immersion, nymphs were placed in a jar containing saturated 
ammonium sulfate (NH4)2SO4 to maintain a RH of about 79% to slightly dehydrate the 
ticks, making them more prone to imbibe fluid during immersion. After incubation of 
nymphs for 72 hours at 79% RH, they were infected with B. burgdorferi by immersing 
them in a culture suspension containing 108 spirochetes/ml for 45 minutes at 32°C. 
Infected nymphs were then washed with sterile distilled water and incubated at 95% RH 
and 25°C for 72 hours in the environmental chamber. Prior to mouse infestation, infected 
ticks were transferred back to the jar at 79% RH. After 72 hours, the infected nymphs 
were ready to be brushed on mice. At either 8-weeks or 12-weeks post-priming, the 
immunized C3H/HeN mice were challenged by brushing 8 to 10 infected nymphs on 
each mouse. To this end mice were sedated, normal saline was provided subcutaneously, 




restrainers covered with white cloth so as to prevent the ticks from escaping the cages 
and to force them onto the mice. Four to six hours post-infestation, mice were housed in 
wire bottom cages for 10 days or until all nymphs feed to repletion and drop off the 
mice, upon which point fallen nymphs were collected and stored in 70% ethanol for 
further molecular analysis of tick spirochete load, as used previously [79]. The 
protective efficacy of the immune response was evaluated by sampling the immunized 
animals at 4-weeks post-challenge. At this point, mice were euthanized following 
IACUC recommended protocols, and blood and tissues were collected from each animal 
to evaluate antibody levels, bacterial clearance and bacterial burden. Collected tissues 
were: spleen, lymph nodes, tibiotarsal joint, heart, bladder and skin. 
Enzyme linked immuno-sorbent assay 
Immunized mice were euthanized at 4-weeks post-challenge, and sera were 
collected to evaluate IgG titers directed against the antigens PepB and the whole cell 
lysates of B. Burgdorferi A3 strain. 96 well plates (Nunc Maxisorb®, Thermo Scientific, 
Ltd.) were coated with (100 ng/well) BSA:PepB antigen, another set of plates were 
coated with the whole cell lysates of B. Burgdorferi A3 strain (107 spirochetes/well). The 
cell lysate was prepared from Borrelia culture that was shifted from RT/pH7.6 to 
37°C/pH6.8. The antigens were coated overnight at 4°C. After washing excess coating 
antigen, serum samples were loaded in 2-fold serial dilutions starting from 1:100 to 
1:102,400 and incubated for 1hr at room temperature. After washing, specific IgG levels 
were detected by adding 1:3000 dilution of the secondary anti-mouse HRP conjugated 




Phenylenediamine dihydrochloride (OPD) (Pierce, Thermo Scientific, Ltd) color 
substrate, and read at the optical density (OD) of 450 nm by using the Bio-Tek 
Synergy™ H1 microplate reader and Gen5™ software (BioTek Instruments Inc., 
Winooski, VT). 
Evaluation of protective efficacy of vaccine candidates 
Immunized mice were euthanized at 4-weeks post-challenge, and blood and 
tissues were collected to evaluate protection of studied antigens. Tissues of skin, spleen, 
lymph nodes, heart, bladder, and tibiotarsal joints were collected for bacterial recovery 
in BSK-II media enriched with 6% iNRS. Following 5 days of incubation at 32°C and 
1% CO2, 100 µl of the cultured media were blindly passed to fresh media, and incubated 
for 15 days before checking the bacterial growth under dark field microscopy [311]. In 
addition, parts of skin, spleen, lymph nodes, and tibiotarsal joints were processed for 
DNA extraction using the High Pure PCR Template Preparation Kit (Roche Applied 
Science, Indianapolis, IN), and they were used to evaluate bacterial burden by 
quantitative real-time PCR as previously illustrated [375].  
Statistical analysis 
All ELISA data were analyzed with Two-way ANOVA to evaluate the statistical 
difference within immunized groups. The quantitative real-time PCR data were analyzed 
by Kruskal-Wallis test to statistically compare between groups. The software Prism 7.0 






Efficacy of TTHc:PepB vaccine candidate 
Evaluation of humoral immune response in the immunized animals post-
challenge was revealed by ELISA. In immunized mice that were challenged at 8 weeks 
post-priming, the anti-PepB antibody titers were relatively high compared to the control 
and TTHc groups, whereas anti-Borrelia antibody levels were comparably high (10,000) 
in all animal groups (Figure 4.1).  
 
 
Furthermore, challenged animals at 12-weeks post-priming, TTHc:PepB 
immunized mice had significantly higher anti-PepB IgG titers (1:10,000) than the 
control and TTHc groups. On the other hand, anti-Borrelia IgG titers were high 
 
Figure 4.1. Elevated IgG antibody titers were detected in the immunized and infected mice 
against peptide B (grey bars) and Borrelia burgdorferi (black bars) at 8 weeks via tick 
challenge. Animals were infested with infected Ixodes scapularis ticks 8-weeks post-priming. 




(1:20,000) in all animal groups (Figure 4.2), denoting that they all got infected through 




Immunized C3H/HeN mice were infested at 8-weeks post-priming with infected 
nymphs. Mice were euthanized at 4-weeks post-challenge, and the bacterial burden was 
evaluated by qPCR in the harvested tissues which include skin, spleen, lymph nodes, and 
tibiotarsal joints. The qPCR results showed that TTHc:PepB significantly reduced 
bacterial burden in immunized mice compared to the control group (Figure 4.3). This 
reduction was especially obvious in skin, spleen, and tibiotarsal joints. Whereas, 
immunized C3H/HeN mice that were challenged with infected nymphs at 12-weeks 
post-priming showed reduction in bacterial burden of skin, spleen, lymph nodes, and 
tibiotarsal joints (Figure 4.4). It was shown that animals that were infected at 8 and 12-
weeks post-priming, TTHc:PepB immunized mice in both groups showed a reduction in 
 
 
Figure 4.2. High IgG antibody titers were detected in the immunized and infected mice 
against peptide B (grey bars) and Borrelia burgdorferi (black bars) at 12 weeks by tick 
challenge. Animals were infested with infected Ixodes scapularis ticks 12-weeks post-priming. 
TTHc:PepB induced significant high anti-PepB IgG titers compared with the control. * Denotes 













Figure 4.3. TTHc:PepB immunized mice display lower bacterial burden 4-weeks post-
infestation with B. burgdorferi infected ticks 8-weeks post-priming. Bacterial burden was 
significantly reduced in mice immunized with TTHc:PepB in all examined tissues including skin 
(A), spleen (B), and joints (D) compared with the control. No significant reduction was observed in 
lymph nodes (C). * Denotes statistical significances (* P value < 0.05; ** P value < 0.01) when 







Figure 4.4. TTHc:PepB immunized mice display lower bacterial burden 4-weeks post-
infestation with B. burgdorferi infected ticks 12-weeks post-priming. Bacterial burden was 
significantly reduced in mice immunized with TTHc:PepB in all examined tissues including 
skin (A), spleen (B), lymph nodes (C), and joints (D) compared with the control. * Denotes 










Figure 4.5. TTHc:PepB immunized mice reduced up to 70% bacterial burden in tissues at 
8 and 12-weeks post infestation with Ixodes scapularis ticks infected with B. burgdorferi. * 
Denotes statistical significances (* P value < 0.05; ** P value < 0.01) when compared with 





Protection was evaluated 4 weeks post-infestation by determining bacterial 
recovery from different tissues by growth in BSK-II medium. When animals were 
infested 8 weeks post-priming, B. burgdorferi was recovered almost from all tissues 
except the bladders from 2 mice, and one spleen and tibiotarsal joint in the group 
receiving TTHc:PepB antigen (Table 4.1). In contrast, in animals that were challenged at 
12-weeks post-priming, Borrelia burgdorferi was recovered from all collected tissues of 
all animal groups, except 1 tissue (bladder) out of 7 in TTHc:PepB group (Table 4.2).  
 
 
Table 4.1. Recovery of B. burgdorferi from sampled tissues of infected and immunized mice at 8 
weeks post-priming and sampled at 4 weeks post-tick infestation  
 
Group Skin Lymph 
Node 
Spleen Bladder Heart Joint Total 
Control 4/4 4/4 4/4 4/4 4/4 4/4 24/24 
TTHc 7/7 7/7 7/7 7/7 7/7 7/7 42/42 
TTHc:PepB 5/5 5/5 4/5 3/5 5/5 4/5 26/30 
No. of tissues positive/No. of tested tissues 
Table 4.2. Recovery of B. burgdorferi from sampled tissues of infected and immunized mice at 
12 weeks post-priming  
Group  Skin Lymph 
Node 
Spleen Bladder Heart Joint Total 
Control 4/4 4/4 4/4 4/4 4/4 4/4 24/24 
TTHc 6/6 6/6 6/6 6/6 6/6 6/6 36/36 
TTHc:PepB 7/7 7/7 7/7 6/7 7/7 7/7 41/42 





In this study, we used TTHc:PepB conjugate to immunize C3H/HeN mice, as it 
was the most efficacious antigen formulation as demonstrated in Chapter III. Our results 
showed that, after tick infection, TTHc:PepB immunized animals are unable to clear the 
infection as observed in Chapter III in which immunized animals were challenged using 
needle infections. Nevertheless, experiments performed in Chapter IV demonstrate a 
significant reduction of up to 70% in the bacterial burden of infected animals immunized 
with the TTHc:PepB antigen formulation. Therefore, the presented results are 
encouraging and deserve further investigation. 
Ixodes ticks are primarily responsible for transmission of LD through their 
hematophagous behavior of feeding. During the blood meal, tick saliva components play 
a major role in the transmission and survival of the tick-borne pathogens. Of these, 
salivary gland proteins such as salp15 was shown to have host immunosuppressive traits 
including inhibition of CD4+ T-cells activation [36]. Also, it facilitates survival of 
spirochetes within the infected host through binding to OspC lipoprotein [35]. There are 
other salivary secretions involve in the survival and enhancement of the infectivity of 
spirochetes within the infected hosts. For instance, Salp20 has been shown to promote 
tick feeding and protect tick-borne pathogens from the complement system [376]. 
Moreover, the tick salivary lectin pathway inhibitor (TSLPI) has been identified in 
Ixodes ticks, and it has a major role in the inhibition of the vertebrate complement 
cascade. Through which it was shown that it enhanced the acquisition and persistence of 




release factor (tHRF) is also another salivary protein that acts by stimulation of 
histamine release in the host, and thereby assist in the tick feeding and transmission of 
tick-borne agents [61].  
The laboratory adapted culture of Borrelia burgdorferi might not be suitable for 
conducting infectious challenges, since it does not exhibit the same protein expression 
patterns as the spirochetes within the ticks that adapt their surface structures to the tick 
environment [377, 378]. However, all the essential plasmids in the B. burgdorferi were 
confirmed by PCR screening method before we used it in the needle challenge study. In 
addition, there are several differences between cultured B. burgdorferi and spirochetes 
growing in vivo [379, 380] that may affect our results in this study. Based on that, it may 
be concluded that the amount and accessibility of the upregulated BB0172 derived 
antigen on the exposed surfaces of spirochetes in vivo may be altered compared to those 
of cultured bacteria. Moreover, other factors that may restrict the interaction of the 
PepB-specific antibodies with B. burgdorferi within the host, are the ability of these 
spirochetes to widely disseminate throughout their host, and also the paucibacillary 
nature of B. burgdorferi infection [381]. Infected ticks have been used for challenge 
protocol in this study. In the infectious tick bite, the inoculated dose of spirochetes is not 
controlled compared to the known dose administered via needle inoculation.  
However, it was previously shown that on week 12 post-priming the anti-Pep B 
antibody levels had reduced to basal levels [79]. The memory immune response was 
effectively triggered in the immunized mice since those animals were shown to mount an 




induced T-cell dependent immune response, which may also account in the reduction of 
bacterial burden we observed in the immunized animals. This is consistent with a 
previous study that showed that CD4+ T cells were required for the control of spirochetes 
load and amelioration of arthritis [382].  
In bacterial recovery, immunized mice were challenged with infected ticks at 8-
weeks post-priming. It was showed that mostly all cultured tissues from the challenged 
mice were able to revive B. burgdorferi. However, anti-PepB antibodies reached their 
peak levels at 8-weeks post-priming, but they were ineffective to confer protection 
against the B. burgdorferi infection. Also, immunization with TTHc:PepB was not quite 
efficient to prevent growth of spirochetes from the cultured tissues following the tick 
challenge at 12-weeks post-priming. Interestingly, it was shown that immunized animals 
tend to shed less Borrelia in the bladder as previously described [79]. Nevertheless, 
mostly all cultured tissues were shown to grow B. burgdorferi, and this is a different 
outcome in contrast to the needle inoculation experiment, in which we observed 66% 
protective rate in terms of bacterial recovery. Nevertheless, after tick infestation we still 
see reduced bacterial burden in the immunized animals compared to the control ones.  
Ixodes ticks are the primary vectors for LD spirochetes. In the ticks, the 
population of spirochetes rapidly and highly expands during ticks feeding [383, 384]. In 
addition, it has been shown that administration of tick salivary gland extract was able to 
increase the dissemination and number of spirochetes in mice [385, 386]. Therefore, the 
viable bacterial inoculum is highly increased at the tick bite site, and it may exceed the 




as mentioned in the introduction, tick saliva proteins will protect Borrelial cells, 
increasing their infectivity. Along those lines, investigators have demonstrated that  
spirochetes show high virulence after they have been primed by a blood meal during tick 
feeding [387].  
Overall, TTHc:PepB did not protect after tick infection, nevertheless, immunized 
animals tend to have significantly lower bacterial burden in different tissues, both at 8-
weeks and 12-weeks post-priming. These results suggests that, other approaches could 
be explored to enhance the immunogenicity of PepB such as it uses in a multi-copy 
peptide or virus-like particles (VLPs), or the use of chimeric or multivalent vaccines 
where anti-tick and anti-LD antigens are administered in the same formulation. 
Furthermore, the improvement in the delivery methods of antigen could also be critical 





SUMMARY AND CONCLUSIONS 
 
Lyme disease (LD) is the most prevalent vector-borne disease in the US, and it is 
transmitted by hard ticks of Ixodes spp. However, vaccine studies are still ongoing to 
develop a safe, efficacious, and broadly protective vaccine candidate against LD 
infection. Nevertheless, there is no currently available commercial vaccine against LD 
for use in human. Therefore, personal preventive measures are necessary to control 
transmission of LD infection, including selection of clothing, tick observation, and use 
of repellents.  
Previously, the evaluation of BB0172 derived-peptides in the murine model of 
LD revealed that the PepB is a promising vaccine candidate that can be further 
investigated. Later, in this study PepB formulation was inserted in a protein scaffold 
BBA34, a lipoprotein of B. burgdorferi located in the outer membrane. BBA34:PepB 
construct was inefficient to stimulate a protective response in immunized mice against 
challenge with B. burgdorferi. Thus, the PepB might not be efficiently enhanced within 
BBA34 molecule in vivo. Therefore, other scaffolding molecules can be studied, and 
further alternative methods could be considered to enhance the immunogenicity of the 
PepB such as using carrier proteins, encapsulated vaccine formulation, and/or 
reformulation of the PepB in a polypeptide context.   
Therefore, in our lab the exploring of novel approaches by studying BB0172 




surface proteins in LD vaccines. The promising results of the conjugated PepB lead us to 
move to the next step of conjugation of the peptide with carrier molecules approved for 
human use.  
In my work, the approach was to study the immunogenicity of the conjugated 
PepB with carrier molecules, including TTHc and CRM197. In that regard, TTHc:PepB 
conjugate was able to elicit protective immune response in immunized mice after needle 
challenge with B. burgdorferi, in which 66% protection was observed based on the 
bacterial recovery data. However, CRM197:PepB also, induced the generation of high 
antibody titers, but it was not as effective as TTHc:PepB.  
TTHc:PepB construct was further evaluated using the tick infection model, as it 
was the most efficacious antigen in the needle challenge protocol. In that regard, in order 
to mimic the natural route of infection, experimentally infected ticks with B. burgdorferi 
were used to challenge the immunized mice. In this part of the study, one group of 
immunized mice were challenged at 8 weeks post-priming to evaluate the efficacy of the 
triggered humoral immune response at its peak level. Whereas, the other group of 
immunized mice were challenged at 12 weeks post-priming to evaluate the efficacy of 
TTHc:PepB in the stimulation of memory B-cells and confer protection against infection 
with B. burgdorferi. In both experiments, TTHc:PepB construct was unable to 
effectively clear the infection in the immunized mice. However, borrelicidal antibodies 
significantly reduced the bacterial burden in infected tissues of the immunized mice 




In future studies, it is important to consider further improvement in the PepB 
formulation to effectively enhance its protective efficacy. Different approaches could be 
explored in that regard including generation of synthetic, repetitive copies of the PepB 
molecule and /or enhance antigen delivery through encapsulated vaccine approach. 
Furthermore, the co-administration of PepB formulation with a potential anti-tick 
vaccine would be more effective to reduce the vector and pathogen burden in a host.  
Furthermore, cross-protection efficacy of PepB can be evaluated by challenge 
against different genospecies of B. burgdorferi sensu lato complex. Based on that, PepB 
based vaccine formulation can be used not only in North America but also in other parts 
of the world as the other genospecies are prevalent in Europe and other parts of Asia.  
In conclusion, study of the PepB formulations revealed that it induced high 
antibody titers in immunized animals, and also the anti-PepB antibodies did not cross 
react with B. burgdorferi lysate. In tick challenge, TTHc:PepB failed to effectively clear 
the infection in the murine model of LD, but significantly reduced bacterial burden in 
immunized individuals. Thus it is our conclusion that PepB formulation requires further 
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